論文・総説 - 田中　真二

1. Shimada S, Tanaka S. The chronicles of hepatocellular carcinoma classification: Subtyping, modeling, and treatment. Hepatology. 2024.02; 79 (2): 261-263. ( PubMed, DOI )

2. Tsukihara S, Akiyama Y, Shimada S, Hatano M, Igarashi Y, Taniai T, Tanji Y, Kodera K, Yasukawa K, Umeura K, Kamachi A, Nara A, Okuno K, Tokunaga M, Katoh H, Ishikawa S, Ikegami T, Kinugasa Y, Eto K, Tanaka S. Delactylase effects of SIRT1 on a positive feedback loop involving the H19-glycolysis-histone lactylation in gastric cancer. Oncogene. 2024; 44 (11): 724- in press. ( PubMed, DOI )

3. Igarashi Y, Akiyama Y, Shimada S, Watanabe S, Hatano M, Kodera K, Okazaki K, Tanji Y, Tsukihara S, Taniai T, Nara A, Yamane M, Kamachi A, Umemura K, Yasukawa K, Ono H, Akahoshi K, Tanabe M, Haruki K, Furukawa K, Ikegami T, Tanaka S. Identification and clinical implications of endogenous retrovirus elements suppressed by SETDB1 in hepatocellular carcinoma. JHEP Reports. 2024; in press. ( DOI )

4. Taniai T, Shimada S, Akiyama Y, Hatano M, Yasukawa K, Igarashi Y, Tsukihara S, Tanji Y, Kodera K, Okazaki K, Haruki K, Nara A, Yagi K, Akahoshi K, Ban D, Asahina Y, Ikegami T, Tanabe M, Tanaka S. Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma. Hepatology. 2024; in press.

5. Yasukawa K, Shimada S, Akiyama Y, Taniai T, Igarashi Y, Tsukihara S, Tanji Y, Umemura K, Kamachi A, Nara A, Yamane M, Akahoshi K, Shimizu A, Soejima Y, Tanabe M, Tanaka S. ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell Reports Medicine. 2024; 6 (4): 102038-in press. ( PubMed, DOI )

6. Igarashi, Y; Akiyama, Y; Shimada, S; Watanabe, S; Hatano, M; Kodera, K; Okazaki, K; Tanji, Y; Tsukihara, S; Taniai, T; Nara, A; Yamane, M; Kamachi, A; Umemura, K; Yasukawa, K; Ono, H; Akahoshi, K; Tanabe, M; Haruki, K; Furukawa, K; Ikegami, T; Tanaka, S. Identification and clinical implications of endogenous retrovirus elements suppressed by SETDB1 in hepatocellular carcinoma JHEP REPORTS. 2025.03; 7 (3): 101307. ( PubMed, DOI )

7. Taniai, T; Shimada, S; Akiyama, Y; Hatano, M; Yasukawa, K; Igarashi, Y; Tsukihara, S; Tanji, Y; Kodera, K; Okazaki, K; Haruki, K; Nara, A; Yagi, K; Akahoshi, K; Ban, DSK; Asahina, Y; Ikegami, T; Tanabe, M; Tanaka, S. Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC HEPATOLOGY. 2025.02; ( PubMed, DOI )

8. Shimada, S; Akiyama, Y; Akahoshi, K; Tanaka, S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma CANCER SCIENCE. 2025.01; 116 1481.

9. Yamane M, Ishikawa Y, Yamashita H, Morimoto K, Asano D, Sugawara T, Watanabe S, Ueda H, Akahoshi K, Ono H, Tanaka S, Tanabe M. Middle segment preserving pancreatectomy versus total pancreatectomy: a comparative analysis of short- and long-term outcomes. Surgery Today. 2024.12; Online ahead of print.

10. Hatano M, Akiyama Y, Shimada S, Yagi K, Akahoshi K, Itoh M, Tanabe M, Ogawa Y, Tanaka S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related hepatocellular carcinoma. Hepatology Communications. 2023.10; 7 (10): e0277.

11. Hatano, M; Akiyama, Y; Shimada, S; Yagi, K; Akahoshi, K; Itoh, M; Tanabe, M; Ogawa, Y; Tanaka, S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC HEPATOLOGY COMMUNICATIONS. 2023.10; 7 (10): ( PubMed, DOI )

12. Yamane M, Ishikawa Y, Asano D, Watanabe S, Ueda H, Akahoshi K, Ono H, Kudo A, Tanaka S, Sugiyama Y, Muro S, Akita K, Tanabe M. Surgical anatomy of the dorsal pancreatic artery: Considering embryonic development. Pancreatology. 2023.09; 23 (6): 697-703. ( PubMed, DOI )

13. Murota Y, Nagane M, Wu M, Santra M, Venkateswaran S, Tanaka S, Bradley N, Taga T, Tabu K. A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells. Inflammation and Regeneration. 2023.09; 43 (1): 46. ( PubMed, DOI )

14. Morimoto K, Ueda H, Asano D, Ishikawa Y, Watanabe S, Akahoshi K, Ono H, Kobayashi M, Okamoto R, Tanaka S, Tanabe M. Incidence and Mechanism of Refractory Postoperative Cholangitis After Hepatectomy with Hepaticojejunostomy. Journal of Gastrointestinal Surgery. 2023.06; 27 (8): 1668-1676.

15. Yagi K, Shimada S, Akiyama Y, Hatano M, Asano D, Ishikawa Y, Ueda H, Watanabe S, Akahoshi K, Ono H, Tanabe M, Tanaka S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma. Sci Rep. 2023.06; 13 (1): 9449. ( PubMed, DOI )

16. Yamamoto Y, Shimada S, Akiyama Y, Tsukihara S, Sugimoto R, Kabashima A, Tokunaga M, Kinugasa Y, Kawakami Y, Tanaka S. RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. Journal of Gastroenterology. 2023.06; 58 (6): 540-553.

17. Yagi K, Ono H, Kudo A, Kinowaki Y, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Tanaka S, Tanabe M. MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens. Sci Rep. 2023.05; 13 (1): 7535. ( PubMed, DOI )

18. Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y, Watanabe S, Ueda H, Akahoshi K, Ogawa K, Kudo A, Akiyama Y, Tanaka S, Tanabe M. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. International Journal of Oncology. 2023.04; 62 (4): 51.

19. Ishii T, Akiyama Y, Shimada S, Kabashima A, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanabe M, Tanaka S. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Cancer Science. 2023.02; 114 (2): 463-476.

20. Shimada, S; Akiyama, Y; Tanaka, S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in HCC CANCER SCIENCE. 2023.02; 114 125.

21. Shimada S, Tanaka S. The chronicles of hepatocellular carcinoma classification: subtyping, modeling and treatment. Hepatology. 2023; in press.

22. Ichihara M, Takahashi H, Nishida N, Ivan C, Okuzaki D, Yokoyama Y, Ohtsuka M, Miyoshi N, Uemura M, Tanaka S, Calin G, Mori M, Doki Y, Eguchi, H, Yamamoto H. Long noncoding RNA 01534 maintains cancer stemness by down-regulating endoplasmic reticulum stress response in colorectal cancer Annals of Gastroenterological Surgery. 2022.12; 7 (3): 458-470. ( PubMed )

23. Ichihara M, Takahashi H, Nishida N, Ivan C, Okuzaki D, Yokoyama Y, Ohtsuka M, Miyoshi N, Uemura M, Tanaka S, Calin G, Mori M, Doki Y, Eguchi, H, Yamamoto H. Long noncoding RNA 01534 maintains cancer stemness by down-regulating endoplasmic reticulum stress response in colorectal cancer Annals of Gastroenterological Surgery. 2022.12; 7 (3): 458-470.

24. Ishii Takeshi, Akiyama Yoshimitsu, Shimada Shu, Kabashima Ayano, Asano Daisuke, Watanabe Shuichi, Ishikawa Yoshiya, Ueda Hiroki, Akahoshi Keiichi, Ogawa Kosuke, Ono Hiroaki, Kudo Atsushi, Tanabe Minoru, Tanaka Shinji. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer CANCER SCIENCE. 2022.11; 114 (2): 463-476.

25. Asano D, Kudo A, Akahoshi K, Maekawa A, Murase Y, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms. Annals of Surgery. 2022.08; 276 (2): e108-e113.

26. Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma International Journal of Clinical Oncology. 2022.07; 27 (7): 1101-1109. ( PubMed, DOI )

27. Kabashima A, Matsuo Y, Ito S, Akiyama Y, Ishii T, Shimada S, Masamune A, Tanabe M, Tanaka S. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Scientific reports. 2022.06; 12 (1): 10466. ( PubMed, DOI )

28. Kato T, Kudo A, Kinowaki Y, Ishikawa Y, Watanabe S, Akahoshi K, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. A novel classification of portal venous tumor invasion to predict residual tumor status after surgery in patients with pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol. 2022.04; 148 (4): 931-941. ( PubMed, DOI )

29. Maekawa A, Kudo A, Kishino Mitsuhiro, Murase Y, Watanabe S, Ishikawa Y, Ueda Hiroki, Akahoshi K, Ogawa K, Ono H, Tanaka S, Kinowaki Y, Tanabe M.. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. Journal of Cancer Research and Clinical Oncology. 2022.03; 148 (3): 697-706. ( DOI )

30. Wang J, Hirose H, Yokoyama Y, Ikeshima R, Tsujimura N, Bonkobara S, Takeda K, Hata T, Inoue A, Hiraki M, Ohtsuka M, Nishida N, Takahashi H, Haraguchi N, Tanaka S, Wu X, Mori M, Yamamoto H.. Functional assessment of miR-1291 in colon cancer cells. International Journal of Oncology. 2022.02; 60 (2): 13. ( PubMed, DOI )

31. Shimada, S; Tanaka, S. Establishment of molecular-immunological subtypes and development of specific models for therapeutic application in HCC CANCER SCIENCE. 2022.02; 113

32. Zhang M, Sugita I, Komura D, Katoh H, Shimada S, Inazawa J, Tanaka S, Ishikawa S. Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma Gastric Cancer. 2022.01; 25 (1): 83-95. ( PubMed )

33. Yamamoto Y, Shimada S, Akiyama Y, Tsukihara S, Sugimoto R, Kabashima A, Tokunaga M, Kinugasa Y, Kawakami Y, Tanaka S. RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. Journal of Gastroenterology. 2022;

34. Ishii T, Akiyama Y, Shimada S, Kabashima A, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanabe M, Tanaka S. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer Cancer Science. 2022;

35. Ichihara M, Takahashi H, Nishida N, Ivan C, Okuzaki D, Yokoyama Y, Ohtsuka M, Miyoshi N, Uemura M, Tanaka S, Calin G, Mori M, Doki Y, Eguchi, H, Yamamoto H. Long noncoding RNA 01534 maintains cancer stemness by down-regulating endoplasmic reticulum stress response in colorectal cancer. Annals of Gastroenterological Surgery. 2022; 7 (3): 458-470. ( PubMed, DOI )

36. Murase Yoshiki, Ono Hiroaki, Ogawa Kosuke, Yoshioka Risa, Ishikawa Yoshiya, Ueda Hiroki, Akahoshi Keiichi, Ban Daisuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers(和訳中) Cancer Science. 2021.11; 112 (11): 4641-4654. ( 医中誌 )

37. Taniai Tomohiko, Shirai Yoshihiro, Shimada Yohta, Hamura Ryoga, Yanagaki Mitsuru, Takada Naoki, Horiuchi Takashi, Haruki Koichiro, Furukawa Kenei, Uwagawa Tadashi, Tsuboi Kazuhito, Okamoto Yasuo, Shimada Shu, Tanaka Shinji, Ohashi Toya, Ikegami Toru. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells(和訳中) Cancer Science. 2021.11; 112 (11): 4570-4579. ( 医中誌 )

38. Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M, ACE 500 study group. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. European journal of cancer (Oxford, England : 1990). 2021.11; 157 373-382. ( PubMed, DOI )

39. Yoshiki Murase, Hiroaki Ono, Kosuke Ogawa, Risa Yoshioka, Yoshiya Ishikawa, Hiroki Ueda, Keiichi Akahoshi, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers Cancer Science. 2021.09; Early View (11): 4641-4654. ( PubMed, DOI )

40. Zhang M, Sugita I, Komura D, Katoh H, Shimada S, Inazawa J, Tanaka S, Ishikawa S. Genomic landscape of a mouse model of diffuse-type gastric adenocarcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2021.08; ( PubMed, DOI )

41. Satoshi Matsui, Hiroaki Ono, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Keiichi Akahoshi, Kosuke Ogawa, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report Jornal of Surgical Case Reports. 2021.08; 2021 (8): rjab368.

42. Masafumi Akasu, Shu Shimada, Ayano Kabashima, Yoshimitsu Akiyama, Masahiro Shimokawa, Keiichi Akahoshi, Atsushi Kudo, Shoji Yamaoka, Minoru Tanabe, Shinji Tanaka. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma Scientific Reports. 2021.08; 11 (1): 16732.

43. Matsui S, Ono H, Asano D, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Kudo A, Tanaka S, Tanabe M. Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report. Journal of surgical case reports. 2021.08; 2021 (8): rjab368. ( PubMed, DOI )

44. Tomotaka Kato,Hiroaki Ono, Mikiya Fujii, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. PLoS One. 2021.06; 16 (6): e0252917.

45. Hiroyuki Ishida, Yoshiya Ishikawa, Keiichi Akahoshi, Hiroki Ueda, Koichiro Morimoto, Hironari Yamashita, Kosuke Ogawa, Hiroaki Ono, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe.. Laparoscopic distal pancreatectomy in a patient with aberrant splenic artery originating from the superior mesenteric artery: A case report 2021.05; 100 (18): e25704.

46. Hiroaki Ono, Tomotaka Kato, Yoshiki Murase, Yutaro Nakamura, Yoshiya Ishikawa, Shuichi Watanabe, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Atsushi Kudo, Yoshimitsu Akiyama, Shinji Tanaka, Hiromichi Ito, Minoru Tanabe. . C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer Scientific Reports. 2021.05; 11 (1): 10078.

47. Ono H, Kato T, Murase Y, Nakamura Y, Ishikawa Y, Watanabe S, Akahoshi K, Ogura T, Ogawa K, Ban D, Kudo A, Akiyama Y, Tanaka S, Ito H, Tanabe M. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Scientific reports. 2021.05; 11 (1): 10078. ( PubMed, DOI )

48. Fukuda Tatsuya, Bouchi Ryotaro, Takeuchi Takato, Amo-Shiinoki Kikuko, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru, Akashi Takumi, Hirayama Kazuhiro, Odamaki Toshitaka, Igarashi Miki, Kimura Ikuo, Tanabe Katsuya, Tanizawa Yukio, Yamada Tetsuya, Ogawa Yoshihiro. Importance of Intestinal Environment and Cellular Plasticity of Islets in the Development of Postpancreatectomy Diabetes DIABETES CARE. 2021.04; 44 (4): 1002-1011. ( PubMed, DOI )

49. Tatsuya Fukuda, Ryotaro Bouchi, Takato Takeuchi, Kikuko Amo-Shiinoki, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe, Takumi Akashi, Kazuhiro Hirayama, Toshitaka Odamaki, Miki Igarashi, Ikuo Kimura, Katsuya Tanabe, Yukio Tanizawa, Tetsuya Yamada and Yoshihiro Ogawa. Importance of Intestinal Environment and Cellular Plasticity of Islets in the Development of Postpancreatectomy Diabetes Diabetes Care. 2021.04; 44 (4): 1002-1011.

50. Maekawa A, Kudo A, Kishino M, Murase Y, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Tanaka S, Kinowaki Y, Tanabe M.. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy Journal of Cancer Research and Clinical Oncology. 2021.04; published online

51. Toshitaka Sugawara, Daisuke Ban, Jo Nishino, Shuichi Watanabe, Aya Maekawa, Yoshiya Ishikawa, Keiichi Akahoshi, Kosuke Ogawa, Hiroaki Ono, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection PLoS One. 2021.04; 16 (4): e0249885.

52. Yoshiki Murase, Atsushi Kudo, Keiichi Akahoshi, Aya Maekawa, Yoshiya Ishikawa, Hiroki Ueda, Kosuke Ogawa, Hiroaki Ono, Shinji Tanaka, Minoru Tanabe. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms Annals of Gastroenterological Surgery. 2021.03; 0 (0): 1-9.

53. Yasuhito Iwao, Daisuke Ban, Satoru Muro, Atsushi Kudo, Shinji Tanaka, Krishna Menon, Minoru Tanabe. Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report Surgical and Radiologic Anatomy. 2021.01;

54. Kikuko Amo-Shiinoki, Katsuya Tanabe, Yoshinobu Hoshii, Hiroto Matsui, Risa Harano, Tatsuya Fukuda, Takato Takeuchi, Ryotaro Bouchi, Tokiyo Takagi, Masayuki Hatanaka, Komei Takeda, Shigeru Okuya, Wataru Nishimura, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe, Takumi Akashi, Tetsuya Yamada, Yoshihiro Ogawa, Eiji Ikeda, Hiroaki Nagano, and Yukio Tanizawa. Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes JCI insight. 2021.01; 6 (1): e143791.

55. Kabashima Ayano, Shimada Shu, Shimokawa Masahiro, Akiyama Yoshimitsu, Tanabe Minoru, Tanaka Shinji. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches Journal of Hepato-Biliary-Pancreatic Sciences . 2021.01; 28 (1): 62-75. ( PubMed, DOI )

56. Yoshiki Murase, Daisuke Ban, Aya Maekawa, Shuichi Watanabe, Yoshiya Ishikawa, Keiichi Akahoshi, Kosuke Ogawa, Hiroaki Ono, Atsushi Kudo, Toshifumi Kudo, Shinji Tanaka, Minoru Tanabe. Successful conversion　surgery　of　distal　pancreatectomy　with　celiac　axis　resection(DP-CAR)　with　double　arterial　reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report Surgical Case Reports. 2020.12;

57. Murase Y, Ban D, Maekawa A, Watanabe S, Ishikawa Y, Akahoshi K, Ogawa K, Ono H, Kudo A, Kudo T, Tanaka S, Tanabe M. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report. Surgical case reports. 2020.12; 6 (1): 302. ( PubMed, DOI )

58. Kimura Koichiro, Tsuchiya Junichi, Kitazume Yoshio, Kishino Mitsuhiro, Akahoshi Keiichi, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru, Tateishi Ukihide. Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study DIAGNOSTICS. 2020.11; 10 (11): ( PubMed, DOI )

59. Koichiro Kimura, Junichi Tsuchiya, Yoshio Kitazume, Mitsuhiro Kishino, Keiichi Akahoshi, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe, Ukihide Tateishi . Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study Diagnostics . 2020.11; 10 (11): 919.

60. 島田 周, 秋山 好光, 田邉 稔, 田中 真二. KDM6A発現低下を特徴とする膵がん予後不良サブタイプにはHDAC阻害剤が著効する 日本癌学会総会記事. 2020.10; 79回 OJ14-6. ( 医中誌 )

61. Asano D, Kudo A, Akahoshi K, Maekawa A, Murase Y, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms. Annals of surgery. 2020.09; ( PubMed, DOI )

62. Asano, Daisuke, Kudo, Atsushi, Akahoshi, Keiichi, Maekawa, Aya, Murase, Yoshiki, Ogawa, Kosuke, Ono, Hiroaki, Ban, Daisuke, Tanaka, Shinji, Tanabe, Minoru . Curative Surgery and Ki-67 Value Rather than Tumor Differentiation Predict the Survival of Patients with High-grade Neuroendocrine Neoplasms Annals of Surgery . 2020.09;

63. Kudo Atsushi, Akahoshi Keiichi, Ito Sakiko, Akashi Takumi, Shimada Shu, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Tateishi Ukihide, Tanaka Shinji, Tanabe Minoru. Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms ANNALS OF SURGERY. 2020.04; 271 (4): 732-739. ( PubMed, DOI )

64. Hiroaki Ono, Atsushi Kudo, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Shinji Tanaka, Minoru Tanabe. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms Journal of Cancer Research and Clinical Oncology. 2020.03; 146 (3): 793-799.

65. Fujita Masashi, Yamaguchi Rui, Hasegawa Takanori, Shimada Shu, Arihiro Koji, Hayashi Shuto, Maejima Kazuhiro, Nakano Kaoru, Fujimoto Akihiro, Ono Atsushi, Aikata Hiroshi, Ueno Masaki, Hayami Shinya, Tanaka Hiroko, Miyano Satoru, Yamaue Hiroki, Chayama Kazuaki, Kakimi Kazuhiro, Tanaka Shinji, Imoto Seiya, Nakagawa Hidewaki. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations EBIOMEDICINE. 2020.03; 53 102659. ( PubMed, DOI )

66. Ono Hiroaki, Kudo Atsushi, Akahoshi Keiichi, Ogura Toshiro, Ogawa Kosuke, Ban Daisuke, Tanaka Shinji, Tanabe Minoru. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2020.03; 146 (3): 793-799. ( PubMed, DOI )

67. Ono S, Dohi O, Yagi N, Sanomura Y, Tanaka S, Naito Y, Sakamoto N, Kato M. Accuracies of Endoscopic Diagnosis of Helicobacter pylori-Gastritis: Multicenter Prospective Study Using White Light Imaging and Linked Color Imaging. Digestion. 2020; 101 (5): 624-630. ( PubMed, DOI )

68. Matsui S, Ogura T, Ban D, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M.. Position of the Pancreas Division Line and Postoperative Outcomes After Distal Pancreatectomy. World Journal of Surgery. 2019.11;

69. Qian Yamin, Wu Xin, Yokoyama Yuhki, Okuzaki Daisuke, Taguchi Mai, Hirose Haruka, Wang Jiaqi, Hata Tsuyoshi, Inoue Akira, Hiraki Masayuki, Ohtsuka Masahisa, Takahashi Hidekazu, Haraguchi Naotsugu, Mizushima Tsunekazu, Tanaka Shinji, Mori Masaki, Yamamoto Hirofumi. E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells CANCER SCIENCE. 2019.11; 110 (11): 3520-3532. ( PubMed, DOI )

70. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies) 日本消化器病学会雑誌. 2019.11; 116 (臨増大会): A893. ( 医中誌 )

71. Qian Yamin, Wu Xin, Yokoyama Yuhki, Okuzaki Daisuke, Taguchi Mai, Hirose Haruka, Wang Jiaqi, Hata Tsuyoshi, Inoue Akira, Hiraki Masayuki, Ohtsuka Masahisa, Takahashi Hidekazu, Haraguchi Naotsugu, Mizushima Tsunekazu, Tanaka Shinji, Mori Masaki, Yamamoto Hirofumi. E-カドヘリン-Fcキメラ蛋白質マトリックスは、癌幹細胞の特性を増強し、結腸癌細胞の間葉系特性を誘導する(E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells) Cancer Science. 2019.11; 110 (11): 3520-3532. ( 医中誌 )

72. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性疾患に関するゲノムシークエンス解析(Genomic sequencing in HBP malignancies) 日本消化器外科学会雑誌. 2019.11; 52 (Suppl.2): 306. ( 医中誌 )

73. Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma. Carcinogenesis. 2019.10;

74. Bo Liu, Atsushi Kudo, Yuko Kinowaki, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Shinji Tanaka, Takumi Akashi, Minoru Tanabe. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms The Japanese Society of Gastroenterology. 2019.09; 54 (9): 819-828.

75. Liu Bo, Kudo Atsushi, Kinowaki Yuko, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Tanaka Shinji, Akashi Takumi, Tanabe Minoru. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms JOURNAL OF GASTROENTEROLOGY. 2019.09; 54 (9): 819-828. ( PubMed, DOI )

76. Jun Yoshino, Daisuke Ban, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Atsushi Kudo, Shinji Tanaka & Minoru Tanabe. The Clinial Implications of Peripancreatic Fluid Collection After Distal Pancreatectomy World Journal of Surgery. 2019.08; 43 (8): 2069-2076.

77. Matsui S, Kudo A, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tanabe M.. Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? Journal of Cancer Research and Clinical Oncology. 2019.08; 145 (8): 2097-2104.

78. Matsui Satoshi, Kudo Atsushi, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Tanaka Shinji, Tanabe Minoru. Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms? JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2019.08; 145 (8): 2097-2104. ( PubMed, DOI )

79. Shimada Shu, Tanaka Shinji. A new era for understanding genetic evolution of multistep carcinogenesis JOURNAL OF GASTROENTEROLOGY. 2019.07; 54 (7): 667-668. ( PubMed, DOI )

80. Watanabe Shuichi, Shimada Shu, Akiyama Yoshimitsu, Ishikawa Yoshiya, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Kudo Atsushi, Yamaoka Shoji, Tanabe Minoru, Tanaka Shinji. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality INTERNATIONAL JOURNAL OF CANCER. 2019.07; 145 (1): 192-205. ( PubMed, DOI )

81. Shimada Shu, Tanaka Shinji. 多段階発癌の遺伝的進化の理解の新時代(A new era for understanding genetic evolution of multistep carcinogenesis) Journal of Gastroenterology. 2019.07; 54 (7): 667-668. ( 医中誌 )

82. Ban Daisuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. HBP外科専門医への教育ロードマップ　腹腔鏡下HBP外科専門医へのロードマップ(Education roadmap to qualified HBP surgeons　Roadmap to the qualified laparoscopic HBP surgeon) 日本肝胆膵外科学会・学術集会プログラム・抄録集. 2019.06; 31回 ESY1-1. ( 医中誌 )

83. Fukamachi Hiroshi, Kim Seon-Kyu, Koh Jiwon, Lee Hye Seung, Sasaki Yasushi, Yamashita Kentaro, Nishikawaji Taketo, Shimada Shu, Akiyama Yoshimitsu, Byeon Sun-ju, Bae Dong-Hyuck, Okuno Keisuke, Nakagawa Masatoshi, Tanioka Toshiro, Inokuchi Mikito, Kawachi Hiroshi, Tsuchiya Kiichiro, Kojima Kazuyuki, Tokino Takashi, Eishi Yoshinobu, Kim Yong Sung, Kim Woo Ho, Yuasa Yasuhito, Tanaka Shinji. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2019.03; 38 (1): 127. ( PubMed, DOI )

84. Shimada Shu, Mogushi Kaoru, Akiyama Yoshimitsu, Furuyama Takaki, Watanabe Shuichi, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Kudo Atsushi, Arii Shigeki, Tanabe Minoru, Wands Jack R., Tanaka Shinji. Comprehensive molecular and immunological characterization of hepatocellular carcinoma EBIOMEDICINE. 2019.02; 40 457-470. ( PubMed, DOI )

85. Okuno Keisuke, Akiyama Yoshimitsu, Shimada Shu, Nakagawa Masatoshi, Tanioka Toshiro, Inokuchi Mikito, Yamaoka Shoji, Kojima Kazuyuki, Tanaka Shinji. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression CARCINOGENESIS. 2019.01; 40 (1): 15-26. ( PubMed, DOI )

86. Ishikawa Y, Ban D, Watanabe S, Akahoshi K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Splenic artery as a simple landmark indicating difficulty during laparoscopic distal pancreatectomy. Asian journal of endoscopic surgery. 2019.01; 12 (1): 81-87. ( PubMed, DOI )

87. Watanabe Yuichiro, Honda Shinya, Konishi Akimitsu, Tanabe Minoru, Tanaka Shinji, Shimizu Shigeomi. Autophagy controls centrosome number by degrading Cep63 CANCER SCIENCE. 2018.12; 109 309.

88. Shimada Shu, Akiyama Yoshimitsu, Tanabe Minoru, Tanaka Shinji. FABP4 overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors CANCER SCIENCE. 2018.12; 109 940.

89. Fukamachi Hiroshi, Nishikawaji Taketo, Shimada Shu, Akiyama Yoshimitsu, Yuasa Yasuhito, Tsuchiya Kiichiro, Tanaka Shinji. Diffuse-type gastric cancers are classified into two clusters, which may be formed via different carcinogenic pathways CANCER SCIENCE. 2018.12; 109 1131.

90. Mizuno Yuki, Shimada Shu, Akiyama Yoshimitsu, Watanabe Shuichi, Aida Tomomi, Ogawa Kosuske, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Kudo Atsushi, Yamaoka Shoji, Tanaka Shinji, Tanabe Minoru. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma CANCER SCIENCE. 2018.12; 109 952.

91. Akiyama Yoshimitsu, Shimada Shu, Tanabe Minoru, Tanaka Shinji. DAXX acts as a tumor suppressor through histone H3.3/H3K9me3 pathway in pancreatic neuroendocrine tumors CANCER SCIENCE. 2018.12; 109 1103.

92. Tanaka Shinji. Molecular target therapy for liver cancer under precision medicine CANCER SCIENCE. 2018.12; 109 634.

93. Keiichi Akahoshi, Hiroaki Ono, Masafumi Akasu, Daisuke Ban, Atsushi Kudo, Atsuko Konta, Shinji Tanaka, Minoru Tanabe. Rapid growth speed of cysts can predict malignant intraductal mucinous papillary neoplasms Journal of Surgical Research. 2018.11; 231 195-200.

94. Keiichi Akahoshi、Daisuke Ban, Ryo Kuboki, Atsushi Oba, Hiroaki Ono, Yusuke Mitsunori, Atsushi Kudo, Shinji Tanaka and Minoru Tanabe. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients Journal of Gastroenterology and Hepatology. 2018.09;

95. Kudo A, Akahoshi K, Ito S, Akashi T, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tateishi U, Tanaka S, Tanabe M.. Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms. Ann Surg.. 2018.07;

96. Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S.. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer. 2018.06; 25 (6): 619-631.

97. 松井　聡、伴　大輔、工藤　篤、田中真二、田邉　稔. 減量切除が有用であった血糖制御不能な悪性インスリノーマの1例 臨床外科. 2018.05; 79 (5): 138-144.

98. Norimichi Chiyonobu, Shu Shimada, Yoshimitsu Akiyama, Kaoru Mogushi, Michiko Itoh, Keiichi Akahoshi, Satoshi Matsumura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shigeki Arii, Takayoshi Suganami, Shoji Yamaoka, Yoshihiro Ogawa, Minoru Tanabe, Shinji Tanaka. Fatty acid binding protein 4 (FABP4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors The American Journal of Pathology. 2018.05; 188 (5):

99. Chiyonobu Norimichi, Shimada Shu, Akiyama Yoshimitsu, Mogushi Kaoru, Itoh Michiko, Akahoshi Keiichi, Matsumura Satoshi, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Kudo Atsushi, Arii Shigeki, Suganami Takayoshi, Yamaoka Shoji, Ogawa Yoshihiro, Tanabe Minoru, Tanaka Shinji. Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors AMERICAN JOURNAL OF PATHOLOGY. 2018.05; 188 (5): 1213-1224. ( PubMed, DOI )

100. Kawai-Kitahata F., Asahina Y., Kakinuma S., Murakawa M., Nitta S., Nagata H., Kaneko S., Inoue E., Miyoshi M., Tsunoda T., Sato A., Nakagawa M., Itsui Y., Azuma S., Tanaka S., Tanabe M., Maekawa S., Enomoto N., Watanabe M.. Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration JOURNAL OF HEPATOLOGY. 2018.04; 68 S667.

101. Shimada Shu, Akiyama Yoshimitsu, Mogushi Kaoru, Ishigami-Yuasa Mari, Kagechika Hiroyuki, Nagasaki Hiromi, Fukamachi Hiroshi, Yuasa Yasuhito, Tanaka Shinji. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models BRITISH JOURNAL OF CANCER. 2018.04; 118 (7): 972-984. ( PubMed, DOI )

102. Yuki Mizuno,Atsushi Kudo,Takumi Akashi,Toshiro Ogura,Kosuke Ogawa,Hiroaki Ono, Yusuke Mitsunori,Daisuke Ban, Shinji Tanaka, Ukihide Tateishi, Minoru Tanabe. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms Journal of Cancer Research and Clinical Oncology. 2018.03; 144 1155-1163.

103. Tanaka Shinji. HCCと膵癌に対するオーダーメイド医療(Precision medicine for HCC and pancreatic cancer) 日本消化器病学会雑誌. 2018.03; 115 (臨増総会): A200. ( 医中誌 )

104. Tanaka Shinji. ゲノム規模解析およびゲノム編集技術の時代に外科腫瘍学に基づいた精密医療(Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology) Annals of Gastroenterological Surgery. 2018.03; 2 (2): 106-115. ( 医中誌 )

105. Yoshiya Ishikawa, Daisuke Ban, Shuichi Watanabe, Keiichi Akahoshi, Hiroaki Ono, Yusuke Mitsunori, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Splenic artery as a simple landmark indicating difficulty during laparoscopic distal pancreatectomy Asian Journal of Endscopic Surgery. 2018.02; 1-7.

106. Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Yamaoka S, Tanabe M, Tanaka S.. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. Sci Rep. . 2018.01; 8 (1):

107. Shimada Shu, Akiyama Yoshimitsu, Tanaka Shinji. Acquired resistance with epigenetic alterations under long-term anti-angiogenic therapy for hepatocellular carcinoma CANCER SCIENCE. 2018.01; 109 60.

108. Fukamachi Hiroshi, Nishikawaji Taketo, Shimada Shu, Akiyama Yoshimitsu, Yuasa Yasuhito, Tuchiya Kiichiro, Tanaka Shinji. Identification of signal transduction pathway in PDX-derived diffuse-type gastric tumor-initiating cells CANCER SCIENCE. 2018.01; 109 880.

109. Mizuno Yuki, Shimada Shu, Akiyama Yoshimitsu, Watanabe Shuichi, Aida Tomomi, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Kudo Atsushi, Arii Shigeki, Yamaoka Shoji, Tanabe Minoru, Tanaka Shinji. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma SCIENTIFIC REPORTS. 2018.01; 8 (1): 106. ( PubMed, DOI )

110. Akiyama Yoshimitsu, Nishikawaji Taketo, Shimada Shu, Yuasa Yasuhito, Tanaka Shinji. Molecular mechanisms of SETDB2 histone methyltransferase overexpression in gastric cancer CANCER SCIENCE. 2018.01; 109 913.

111. Oba Atsushi, Ban Daisuke, Kudo Atsushi, Kirimura Susumu, Ito Hiromitsu, Matsumura Satoshi, Mitsunori Yusuke, Aihara Arihiro, Ochiai Takanori, Tanaka Shinji, Tanabe Minoru. Correlation Between the Acquisition of Resistance to Gemcitabine Therapy and the Expression of HuR in Pancreatic Ductal Adenocarcinoma: A Case Report INTERNATIONAL SURGERY. 2018; 103 (1-2): 116-120. ( DOI )

112. Tanaka, S. Molecular Analysis for Therapeutic Targets of Pancreatic Cancer MOLECULAR DIAGNOSIS AND TARGETING FOR THORACIC AND GASTROINTESTINAL MALIGNANCY. 2018; 127-144. ( DOI )

113. Oba A, Kudo A, Kishino M , Akashi T, Katsuta E, Akahoshi E, Iwao Y, Ono H, Mitsunori Y, Ban D , Tanaka S, Eishi Y, Tateishi U, Tanabe M. A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors. Journal of Gastroenterology. 2017.10; 52 (10): 1140-1146. ( PubMed, DOI )

114. Ishikawa Y, Ban D, Matsumura S, Mitsunori Y, Ochiai T, Kudo A, Tanaka S, Tanabe M. Surgical pitfalls of jejunal vein anatomy in pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2017.07; 4 (7): 394-400. ( DOI )

115. Ueda H, Ban D, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Tanabe M. Refractory long-term cholangitis after pancreaticoduodenectomy: a retrospective study. World Journal of Surgery. 2017.07; 41 (7): 1882-1889. ( DOI )

116. Ohata Y, Shimada S, Akiyama Y, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S . Acquired resistance with epigenetic alterations under long-term anti-angiogenic therapy for hepatocellular carcinoma. Molecular Cancer Therapeutics. 2017.06; 16 (6): 1155-1165. ( DOI )

117. Ohata Yoshiteru, Shimada Shu, Akiyama Yoshimitsu, Mogushi Kaoru, Nakao Keisuke, Matsumura Satoshi, Aihara Arihiro, Mitsunori Yusuke, Ban Daisuke, Ochiai Takanori, Kudo Atsushi, Arii Shigeki, Tanabe Minoru, Tanaka Shinji. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma MOLECULAR CANCER THERAPEUTICS. 2017.06; 16 (6): 1155-1165. ( PubMed, DOI )

118. Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S . ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of Hepatology. 2017.05; 66 (5): 942-951. ( DOI )

119. Akahoshi K, Ochiai T, Takaoka A, Kitamura T, Ban D, Kudo A, Tanaka S, Tanabe M. Emergency Cholecystectomy for Patients on Antiplatelet Therapy. Am Surg. 2017.05; 83 (5): 486-490. ( PubMed )

120. Ban Daisuke, Asano Daisuke, Akahoshi Keiichi, Ono Hiroaki, Mitsunori Yusuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Borderline resectable膵癌に対するCT画像の特徴に応じた至適管理(The optimal management depending on the features of CT imaging of borderline resectable pancreatic cancer) Journal of Hepato-Biliary-Pancreatic Sciences. 2017.05; 24 (Suppl.1): A165. ( 医中誌 )

121. Chiyonobu Norimichi, Ono Hiroaki, Iwao Yasuhito, Matsumura Satoshi, Mitsunori Yusuke, Ban Daisuke, Ochiai Takanori, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. IPMNの術前画像検査において造影される結節の臨床的意義(Clinical significance of enhancing nodules in preoperative imaging studies of IPMN) Journal of Hepato-Biliary-Pancreatic Sciences. 2017.05; 24 (Suppl.1): A369. ( 医中誌 )

122. Ono Hiroaki, Akahoshi Keiichi, Iwao Yasuhito, Matsumura Satoshi, Mitsunori Yuusuke, Ban Daisuke, Ochiai Takanori, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. IPMNに対する手術後におけるリンパ節転移の臨床評価(Clinical evaluation of lymph node metastasis after surgery of IPMN) Journal of Hepato-Biliary-Pancreatic Sciences. 2017.05; 24 (Suppl.1): A115. ( 医中誌 )

123. Akahoshi Keiichi, Ochiai Takanori, Takaoka Ayumi, Kitamura Takuya, Ban Daisuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Emergency Cholecystectomy for Patients on Antiplatelet Therapy AMERICAN SURGEON. 2017.05; 83 (5): 486-490.

124. Kawai-Kitahata F., Asahina Y., Kakinuma S., Murakawa M., Nitta S., Nagata H., Kaneko S., Otani S., Asano Y., Inoue E., Miyoshi M., Tsunoda T., Sato A., Nakagawa M., Itsui Y., Azuma S., Tanaka S., Tanabe M., Maekawa S., Enomoto N., Watanabe M.. Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection JOURNAL OF HEPATOLOGY. 2017; 66 (1): S227.

125. Furuyama T, Kudo A, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Tanaka S, Tanabe M. Preoperative direct bilirubin to prothrombin time ratio index to prevent liver failure after minor hepatectomy J Hepatobiliary Pancreat Sci. 2016.12; 23 (12): 763-770. ( DOI )

126. Munakata K, Uemura M, Tanaka S, Kawai K, Kitahara T, Miyo M, Kano Y, Nishikawa S, Fukusumi T, Takahashi Y, Hata T, Nishimura J, Takemasa I, Mizushima T, Ikenaga M, Kato T, Murata K, Carethers JM, Yamamoto H, Doki Y, Mori M. Cancer stem-like properties in colorectal cancer cells with low proteasome activity Clinical Cancer Research. 2016.11; 22 (21): 5277-5286.

127. Watanabe Y, Honda S, Konishi A, Satoko Arakawa S, Murohashi M, Yamaguchi H, Torii S, Tanabe M, Tanaka S, Warabi E, Shimizu S. Autophagy controls centrosome number by degrading Cep63. Nature Communications. 2016.11; 21 (7): 13508. ( DOI )

128. Nishikawaji T, Akiyama Y, Shimada S, Kojima K, Kawano T, Eishi Y, Yuasa Y, Tanaka S. Overexpression of histone methyltransferase SETDB2 acts an oncogene in gastric cancer Oncotarget. 2016.10; 7 (41): 67251-67265. ( DOI )

129. Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. J Gastroenterol. . 2016.09; 51 (9): 910-922.

130. Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors Journal of Gastroenterology. 2016.09; 51 (9): 910-922. ( DOI )

131. Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T.. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. . 2016.08; 23 (8): 480-488.

132. Tanaka S. Cancer stem cells as therapeutic targets Human Stem Cell Toxicity (ed. Sherley JL). 2016.08; 280-294. ( DOI )

133. Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Tanabe M. . Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016.08; 23 (8): 480-488. ( DOI )

134. Eriko Katsuta, Atsushi Kudo, Takumi Akashi, Yusuke Mitsunori, Satoshi Matsumura, Arihiro Aihara, Daisuke Ban, Takanori Ochiai, Shinji Tanaka, Yoshinobu Eishi, Minoru Tanabe. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm J Cancer Res Clin Oncol . 2016.06; 142 1299-1306.

135. Katsuta E, Kudo A, Akashi T, Mitsunori Y, Matsumura S, Aihara A, Ban D, Ochiai T, Tanaka S, Eishi Y, Tanabe M. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm Journal of Cancer Research and Clinical Oncology. 2016.06; 142 (6): 1299-1309. ( DOI )

136. Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M. Proteasome activity is required for the initiation of precancerous pancreatic lesions Scientific Reports. 2016.05; 6 27044. ( DOI )

137. 4) Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Sayuri Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, Sakamoto M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Journal of Gastroenterology. 2016.05; 51 (5): 473-486. ( DOI )

138. Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, Iwai N, Mitsuyoshi H, Sumida Y, Moriguchi M, Yamaguchi K, Nishikawa T, Umemura A, Naito Y, Tanaka S, Arii S, Itoh Y. Genome-wide DNA methylation analysis in hepatocellular carcinoma Oncology Reports. 2016.04; 35 (4): 2228-2236. ( DOI )

139. Tanaka S.. Molecular pathogenesis and targeted therapy of pancreatic cancer. Annals of Surgical Oncology. 2016.02; Suppl (2): 197-205.

140. 4) Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M . CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells International Journal of Oncology. 2016.02; 48 (2): 657-669.

141. Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M.. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. Int J Oncol. . 2016.02; 48 (2): 657-669.

142. Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. A novel Aurora/VEGFR dual kinase inhibitor as treatment for hepatocellular carcinoma Cancer Science. 2015; 106 (8): 1016-1022.

143. Ban D, Kudo A, Irie T, Ochiai T, Aihara A, Matusmura S, Tanaka S, Tanabe M. Advances in reduced port laparoscopic liver resection Asian Journal of Endoscopic Surgery. 2015; 8 (1): 11-15.

144. Tanaka S. Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers Journal of Hepato-Biliary-Pancreatic Sciences. 2015; 22 (7): 531-537.

145. Watanabe Y, Yamamoto H, Oikawa R, Toyota M, Yamamoto M, Kokudo N, Tanaka S, Arii S, Yotsuyanagi H, Koike K, Itoh F. DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences Genome Research. 2015; 25 (3): 328-337.

146. Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Tanaka S, Arii S, Itoh Y. EVI1, a target gene for amplification at 3q26, antagonizes TGF-beta-mediated growth inhibition in hepatocellular carcinoma Cancer Science. 2015; 106 (7): 929-937.

147. Ban D, Kudo A, Ito H, Mitsunori Y, Matsumura S, Aihara A, Ochiai T, Tanaka S, Tanabe M, Itano O, Kaneko H, Wakabayashi G. The difficulty of laparoscopic liver resection Updates in Surgery. 2015; 67 (2): 123-128.

148. Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection American Journal of Surgery. 2015; 209 (1): 199-205.

149. Sakamoto A, Akiyama Y, Shimada S, Zhu WG, Yuasa Y, Tanaka S. DNA methylation in the exon 1 region and complex regulation of Twist1 expression in gastric cancer PLoS ONE. 2015; 10 (12): e0145630.

150. Miura T, Ban D, Tanaka S, Mogushi K, Kudo A, Matsumura S, Mitsunori Y, Ochiai T, Tanaka H, Tanabe M. Distinct clinicopathological phenotype of hepatocellular carcinoma with EOB-MRI hyperintensity: association with gene expression signature American Journal of Surgery. 2015; 210 (3): 561-569.

151. Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M. A novel therapeutic combination targeting sequentially Aurora B and Bcl-xL in hepatocellular carcinoma Annals of Surgical Oncology. 2015; 22 (9): 3079-3086.

152. Kudo A, Matusmura S, Ban D, Irie T, Ochiai T, Tanaka S, Arii S, Tanabe M.. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol. Res.. 2014.12; 44 (14): E437-E446. ( PubMed, DOI )

153. Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M.. A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma. Ann. Surg. Oncol.. 2014.12; ( PubMed, DOI )

154. Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M.. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J. Gastroenterol.. 2014.09; 49 (9): 1352-1361. ( PubMed, DOI )

155. Kudo A, Tanaka S, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Arii S.. Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion. Am. J. Surg.. 2014.06; 207 (6): 863-869. ( PubMed, DOI )

156. Miura T, Ban D, Koyama T, Kudo A, Ochiai T, Irie T, Nakamura N, Tanaka S, Arii S.. Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases. Surg. Today. 2014.05; 44 (5): 976-981. ( PubMed, DOI )

157. Katsuta E, Tanaka S, Mogushi K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Tanabe M, Arii S.. Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma. Am. J. Surg.. 2014.05; ( PubMed, DOI )

158. Kudo A, Igari T, Kumagai J, Tanaka S, Ban D, Noguchi N, Irie T, Nakamura N, Arii S.. A simple index to predict liver functional reserve after hepatectomy. Hepatogastroenterology. 2014.04; 61 712-716.

159. Ogawa K, Tanaka S, Matsumura S, Murakata A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, Arii S.. EpCAM-targeted therapy for human hepatocellular carcinoma. Ann. Surg. Oncol.. 2014.04; 21 (4): 1314-1322. ( PubMed, DOI )

160. Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S.. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study. J. Gastroenterol.. 2014.03; 49 (3): 502-510. ( PubMed, DOI )

161. Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology. 2014.01; 86 (1): 53-62. ( PubMed, DOI )

162. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, Fukusumi T, Satoh T, Tanaka S, Ogawa K, Mori M, Doki Y, Ishii H. Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncology Reports. 2014; 86 (1): 53-62.

163. Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma; clinical and biological significance. Hepatology. 2013; 57 (4): 1436-1447. ( PubMed, DOI )

164. Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. . Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication. Hepatology, 58:218-228, 2013 Hepatology. 2013; 58 218 -228.

165. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology, 143:234-245, 2012 Gastroenterology, 143:234-245, 2012 . 2012;

166. Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. . Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. Clinical Cancer Research, 18:3541-3551, 2012 Clinical Cancer Research, 18:3541-3551, 2012. 2012;

167. Tanaka S, Arii S.. Tanaka S, Arii S. Molecular targeted therapy in hepatocellular carcinoma. Seminars in Oncology, 39:486-92, 2012 Seminars in Oncology, 39:486-92, 2012. 2012;

168. Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. . Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. Oxidative stress pathways in non-cancerous human liver tissue to predict hepatocellular carcinoma recurrence; a prospective multi-center study. Hepatology, 54:1273-1281, 2011 Hepatology, 54:1273-1281, 2011. 2011;

169. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Gene expression signature of the gross morphology in hepatocellular carcinoma. Annals of Surgery, 253:94-100, 2011 Annals of Surgery, 253:94-100, 2011. 2011;

170. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. Journal of Hepatology, 52:63-71, 2010 Journal of Hepatology, 52:63-71, 2010. 2010;

171. Tanaka S, Arii S.. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 100:1-8, 2009 Cancer Science, 100:1-8, 2009. 2009;

172. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H.. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. British Journal of Surgery, 95:611-619, 2008 British Journal of Surgery, 95:611-619, 2008. 2008;

173. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. . Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. Journal of the American College of Surgeons, 204:1-6, 2007 Journal of the American College of Surgeons, 204:1-6, 2007. 2007;

174. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. Journal of the National Cancer Institute, 98:491-498, 2006 Journal of the National Cancer Institute, 98:491-498, 2006. 2006;

175. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. Journal of Hepatology, 43:854-62, 2005 Journal of Hepatology, 43:854-62, 2005. 2005;

176. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. The newly established human hepatocyte cell line: application for the bioartificial liver. Journal of Hepatology, 42:557-64, 2005 Journal of Hepatology, 42:557-64, 2005. 2005;

177. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. . Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. Journal of Clinical Oncology, 22:4165-73, 2004 Journal of Clinical Oncology, 22:4165-73, 2004. 2004;

178. Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. . Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 112:184-9, 2004 International Journal of Cancer, 112:184-9, 2004. 2004;

179. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. . Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 127(4):1110-22, 2004 Gastroenterology, 127(4):1110-22, 2004. 2004;

180. Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. . Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma. Hepatology, 37:1122-9, 2003 Hepatology, 37:1122-9, 2003. 2003;

181. Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. . Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology, 125:1563-4, 2003 Gastroenterology, 125:1563-4, 2003. 2003;

182. Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology, 35:861-7, 2002 Hepatology, 35:861-7, 2002. 2002;

183. Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant WISPs as targets for gastrointestinal carcinomas. Gastroenterology, 123:392-3, 2002 Gastroenterology, 123:392-3, 2002. 2002;

184. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene, 20:5525-32, 2001 Oncogene, 20:5525-32, 2001. 2001;

185. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. . Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. Journal of Hepatology, 35:74-79, 2001 Journal of Hepatology, 35:74-79, 2001. 2001;

186. Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. . Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Research, 61:2145-2153, 2001 Cancer Research, 61:2145-2153, 2001. 2001;

187. Yamashita Yi, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Sugimachi K. . Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Research. 2001; 61 1005-1012.

188. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. Expression and anti-tumor effects of TRAIL in human cholangiocarcinoma. Hepatology, 32:523-527, 2000 Hepatology, 32:523-527, 2000. 2000;

189. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. Journal of Clinical Investigation, 103(3): 341-5, 1999 1999;

190. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, Ueo H, Takesako K, Akiyoshi T. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunology and Immunotherapy, 48(4): 189-94, 1999 1999;

191. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. International Journal of Oncology, 15(4): 687-92, 1999 1999;

192. Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M. G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Research, 59(5): 1096-101, 1999 Cancer Research, 59(5): 1096-101, 1999. 1999;

193. Watanabe M, Kuwano H, Tanaka S, Toh Y, Sadanaga N, Sugimachi K. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus. Cancer, 85(11): 2322-8, 1999 1999;

194. Shimada M, Hasegawa H, Gion T, Shirabe K, Taguchi K, Takenaka K, Tanaka S, Sugimachi K. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology, 46(28): 2469-75, 1999 1999;

195. Watanabe M, Kuwano H, Tanaka S, Toh Y, Masuda H, Sugimachi K. A significant morphological transformation is recognized in human esophageal cancer cells with an amplification/overexpression of the Cyclin D1 gene. International Journal of Oncology, 15(6): 1103-1108, 1999 1999;

196. Mori M, Shiraishi T, Tanaka S, Yamagata M, Mafune K, Tanaka Y, Ueo H, Barnard GF, Sugimachi K. Lack of DMBT1 expression in oesophageal, gatric and colon cancer. British Journal of Cancer, 79(2): 211-213, 1999 1999;

197. de la Monte SM, Ganju N, Tanaka S, Banerjee K, Karl PJ, Brown NV, Wands JR.. Differential effects of ethanol on insulin-signaling through the insulin receptor substrate-1. Alcoholism, Clinical and Experimental Research. 1999; 23 (5): 770-777. ( PubMed, DOI )

198. Tanaka S, Komori K, Sugimachi K. Cytomegalovirus infection in aortic aneurysms. Journal of Vascular Surgery, 27(3): 587-588, 1998 1998;

199. Mohr L, Tanaka S, Wands JR. Ethanol inhibits hepatocytes proliferation through the IRS-1 signal transduciton pathway in transgene mice. Gastroenterology, 115(6): 1558-65, 1998 1998;

200. Shiraishi T, Mori M, Tanaka S, Sugimachi K, Akiyoshi T. Identification of cystatin B in human esophageal carcinoma using differential displays in which the gene expression is related to lymph node metastasis. International Journal of Cancer, 79(2): 175-178, 1998 1998;

201. Mimori K, Mori M, Shiraishi T, Tanaka S, Haraguchi M, Ueo H, Shirasaka C, Akiyoshi. Expression of ornithine decarboxylase mRNA and c-myc mRNA in breast tumours. International Journal of Oncology, 12(3):597-601, 1998 1998;

202. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K, Sueishi K.. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circulation Research. 1998; 82 (2): 147-156.

203. Shibata K, Mori M, Tanaka S, Kitano S, Akiyoshi T. Identification and cloning of human G-protein gamma 7, down-regulated in pancreatic cancer. Biochemical and Biophysical Research Communications, 246(1): 205-209, 1998 1998;

204. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K.. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K. A novel variant of human Grb7 is associated with invasive esophageal carcinoma. Journal of Clinical Investigation, 102(4): 821-827, 1998 Journal of Clinical Investigation, 102(4): 821-827, 1998. 1998;

205. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. . Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proceedings of the National Academy of Sciences, USA, 95(17): 10164-10169, 1998 Proceedings of the National Academy of Sciences, USA, 95(17): 10164-10169, 1998. 1998;

206. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K. Co-expression of Grb7 with EGFR or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Research, 57: 28-31, 1997 1997;

207. Mimori K, Mori M, Begum NA, Tanaka S, Haraguchi M, Ueo H, Karimine N, Akiyoshi T, Barnard GF. Clinical significance of integrin alpha 6 mRNA expression in gastric carcinoma. International Journal of Oncology, 11(5): 959-964, 1997 1997;

208. Wands JR, Lavaissiere L, Moradopour D, de la Monte S, Mohr L, Nicolau C, Tanaka S. Immunological approach to hepatocellular carcinoma. Journal of Viral Hepatitis, 4(4): 60-74, 1997 1997;

209. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nature Medicine, 3(6): 593, 1997 1997;

210. Tanaka S, Smidt EV, Mohr L, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology, 26: 598-604, 1997 1997;

211. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K. Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Digestive Diseases and Sciences, 41(1): 208-15, 1996 1996;

212. Yonemitsu Y, Nakagawa K, Tanaka S, Mori R, Sugimachi K, Sueishi K.. In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: possible pathogenic role in sustained chronic inflammatory reaction. Laboratory Investigation. 1996; 74 (4): 723-736.

213. Tanaka S, Wands JR. Tanaka S, Wands JR. Insulin receptor substrate-1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor-beta1 induced apoptosis. Cancer Research, 56: 3391-4, 1996 Cancer Research, 56: 3391-4, 1996. 1996;

214. Tanaka S, Ito T, Wands JR.. Tanaka S, Ito T, Wands JR. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with Grb2 and Syp signaling molecules. Journal of Biological Chemistry, 271(24): 14610-6, 1996 Journal of Biological Chemistry, 271(24): 14610-6, 1996 . 1996;

215. Tanaka S, Wands JR. Tanaka S, Wands JR. A carboxy-terminal truncated IRS-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. Journal of Clinical Investigation, 98(9): 2100-8, 1996 Journal of Clinical Investigation, 98(9): 2100-8, 1996. 1996;

216. Mimori K, Mori M, Tanaka S, Akiyoshi T, Sugimachi K. The overexpression of elongation factor 1 gamma mRNA in gastric carcinoma. Cancer, 75(6): 1446-9, 1995 1995;

217. Li YY, Minagawa H, Tanaka S, Mori R. Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice. Antiviral Research, 27(1-2): 111-21, 1995 1995;

218. Minagawa H, Tanaka S, Toh Y, Mori R. Detection of herpes simplex virus type 1-encoded RNA by polymerase chain reaction: different pattern of viral RNA detection in latently infected murine trigeminal ganglia following in vitro or in vivo reactivation. Journal of General Virology, 75(3): 647-50, 1994 1994;

219. Tanaka S, Komori K, Okadome K, Sugimachi K, Mori R. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. Journal of Vascular Surgery, 20(2): 235-43, 1994 1994;

220. Mori M, Watanabe M, Tanaka S, Mimori K, Kuwano H, Sugimachi K. Epstein-Barr virus-associated carcinomas of the esophagus and stomach. Archives of Pathology & Laboratory Medicine, 118(10): 998-1001, 1994 1994;

221. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Research, 53: 2884-7, 1993 1993;

222. Hayashi H, Sugio K, Matsumata T, Adachi E, Urata K, Tanaka S, Sugimachi K. The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. Liver, 13(5): 279-81, 1993 1993;

223. Toh Y, Liu Y, Tanaka S, Mori R. Nucleotide sequence of the major DNA-binding protein gene of herpes simplex virus type 2 and a comparison with the type 1. Archives of Virology, 129(1-4): 183-96, 1993 1993;

224. Toh Y, Tanaka S, Liu Y, Hidaka Y, Mori R. Molecular characterization of naturally occurring glycoprotein C-negative herpes simplex virus type 1. Archives of Virology, 129(1-4): 119-30, 1993 1993;

225. Tanaka S, Toh Y, Mori R. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Archives of Virology, 131: 61-73, 1993 1993;

226. Tanaka S, Toh Y, Minagawa H, Mori R, Sugimachi K, Minamishima Y. Reactivation of cytomegalovirus in patients with cirrhosis: analysis of 122 cases. Hepatology, 16(6): 1409-14, 1992 1992;

227. Toh Y, Kuwano H, Tanaka S, Baba K, Matsuda H, Sugimachi K, Mori R. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer, 70(9): 2234-8, 1992 1992;

228. Tanaka S, Toh Y, Mori R, Komori K, Okadome K, Sugimachi K. Possible role of cytomegalovirus in the pathogenesis of inflammatory aortic diseases. Journal of Vascular Surgery, 16(2): 274-9, 1992 1992;

229. 田中真二. 肝癌治療とサブタイプ分類のクロニクル 肝胆膵. 2024.04; 88 (4): 385-388.

230. 蒲池厚志、秋山好光、島田周、波多野恵、田中真二. 胆道癌におけるエピゲノム異常とその臨床的意義 胆と膵. 2024.08; 45 (8): 835-843.

231. 波多野恵、秋山好光、島田周、田中真二. 脂肪負荷に対する肝癌の耐性機序 肝胆膵. 2024.04; 88 (4): 459-465.

232. 丹治 芳明，島田 周，田中 真二. 膵がんにおける最新研究と治療法の展望. BIO Clinica. 2023.10; 38 (10): 844-849.

233. 山下宏成、石川喜也、浅野大輔、渡邊秀一、上田浩樹、赤星径一、小野宏晃、工藤　篤、田中真二、田邉　稔. 肝外側区域切除術:腹腔鏡下手術 臨床外科増刊号. 2023.10; 78 (11): 276-280.

234. 浅野大輔、吉野　潤、石川喜也、渡邊秀一、上田浩樹、小野宏晃、赤星径一、工藤　篤、田中真二、田邉　稔. 総論 市中病院でもできるビデオ撮影と編集のコツ 臨床外科. 2023.10; 78 (10): 1205-1209.

235. 谷合 智彦, 島田 周, 秋山 好光, 波多野 恵, 田中 真二. 【臨床医に必要な肝癌Basic Oncology】がんゲノム　トランスクリプトーム解析に基づく予後不良型肝細胞癌の分子生物学的特徴 肝胆膵. 2023.05; 86 (5): 579-585. ( 医中誌 )

236. 奈良 篤, 島田 周, 田中 真二. 【臨床医に必要な肝癌Basic Oncology】免疫微小環境　肝癌のゲノム変異と免疫治療抵抗性の獲得メカニズム 肝胆膵. 2023.05; 86 (5): 623-630. ( 医中誌 )

237. 谷合 智彦, 島田 周, 秋山 好光, 波多野 恵, 田中 真二. MTM/VETCを形成する高悪性度肝細胞癌同種移植モデルの作製とその分子生物学的特徴および癌免疫微小環境の解明. 肝胆膵. 2023.04; 86 (4): 542-543.

238. 永田 尚義, 寺井 崇二, 田中 真二. 【マイクロバイオームが切り拓く肝胆膵の新未来】マイクロバイオームの最新トピックス 肝胆膵. 2023.03; 86 (3): 413-428. ( 医中誌 )

239. 梅村 謙太郎, 島田 周, 田中 真二. 【肝胆膵診療のDX(デジタルトランスフォーメーション)新時代】肝胆膵診療のデジタル化の現状　肝癌ゲノム研究におけるデジタル化の現状と展望 肝胆膵. 2023.02; 86 (2): 191-199. ( 医中誌 )

240. Ishii Takeshi, Akiyama Yoshimitsu, Shimada Shu, Kabashima Ayano, Asano Daisuke, Watanabe Shuichi, Ishikawa Yoshiya, Ueda Hiroki, Akahoshi Keiichi, Ogawa Kosuke, Ono Hiroaki, Kudo Atsushi, Tanabe Minoru, Tanaka Shinji. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer CANCER SCIENCE. 2022.11; 114 (2): 463-476. ( PubMed, DOI )

241. 赤星径一、工藤　篤、上田浩樹、小野宏晃、田中真二、田邉　稔. 神経内分泌腫瘍のオミックス解析 消化器内科. 2022.10; 4 (9): 13-17.

242. 石川 喜也, 浅野 大輔, 渡辺 秀一, 上田 浩樹, 赤星 径一, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【術前画像の読み解きガイド-的確な術式選択と解剖把握のために】肝臓　腹腔鏡下肝左葉切除　解剖把握と術中所見 臨床外科. 2022.10; 77 (11): 217-221. ( 医中誌 )

243. 赤星 径一, 工藤 篤, 上田 浩樹, 小野 宏晃, 田中 真二, 田邉 稔. 【消化器領域の神経内分泌腫瘍の最新の知見】神経内分泌腫瘍のオミックス解析 消化器内科. 2022.10; 4 (9): 13-17. ( 医中誌 )

244. 浅野大輔、工藤　篤、石川喜也、渡邊秀一、上田浩樹、小野宏晃、赤星径一、田中真二、田邉　稔. 神経内分泌腫瘍ーhg-NENsの治療戦略ー 肝胆膵. 2022.06; 84 (6): 839 -844.

245. 山下宏成、小川康介、木脇祐子、渡邉亮輔、石田啓之、森本紘一朗、八木宏平、前川　彩、村瀬芳樹、石井　武、菅原俊喬、石川喜也、上田浩樹、赤星径一、小野宏晃、工藤　篤、田中真二、明石　巧、田邉　稔. 術前に肝粘液嚢胞腺癌を疑うも、術中所見と病理所見にてIPNBの診断に至った1例 Liver Cancer. 2022.06; 27 (47): 19-21.

246. 工藤 篤, 池田 公史, 田中 真二. 【膵神経内分泌腫瘍-新たなる胎動2022-】膵神経内分泌腫瘍の最新トピックス 肝胆膵. 2022.06; 84 (6): 853-866. ( 医中誌 )

247. 浅野 大輔, 工藤 篤, 石川 喜也, 渡邊 秀一, 上田 浩樹, 小野 宏晃, 赤星 径一, 田中 真二, 田邉 稔. 【膵神経内分泌腫瘍-新たなる胎動2022-】集学的治療　神経内分泌腫瘍　hg-NENsの治療戦略 肝胆膵. 2022.06; 84 (6): 839-844. ( 医中誌 )

248. 石川喜也、上田浩樹、浅野大輔、渡邊秀一、赤星径一、小野宏晃、工藤　篤、田中真二、田邉　稔. 腹腔鏡下膵体尾部切除術 消化器外科. 2022.04; 45 (4): 461-465.

249. 石川 喜也, 上田 浩樹, 浅野 大輔, 渡邊 秀一, 赤星 径一, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【腹腔鏡下・ロボット支援下手術のリカバリーショット　私ならこうする!】腹腔鏡下膵体尾部切除術 消化器外科. 2022.04; 45 (4): 461-465. ( 医中誌 )

250. 赤星径一、上田浩樹、小野宏晃、渡邊秀一、石川喜也、浅野大輔、工藤　篤、田中真二、田邉　稔. 膵神経内分泌腫瘍における多層オミックス解析 胆と膵. 2022.02; 43 (2): 95-98.

251. Ono Hiroaki, Akahoshi Keiichi, Tanaka Shinji, Tanabe Minoru. RRM1 contributes to the malignant transformation by altering extracellular matrix proteins in pancreatic cancer cells CANCER SCIENCE. 2022.02; 113 847.

252. Tanaka Shinji. Surgical oncology to develop novel targeted and immunotherapies for hepato-biliary-pancreatic cancer CANCER SCIENCE. 2022.02; 113 1255.

253. 赤星 径一, 上田 浩樹, 小野 宏晃, 渡邊 秀一, 石川 喜也, 浅野 大輔, 工藤 篤, 田中 真二, 田邉 稔. 【膵神経内分泌腫瘍の病態解明と診療戦略】膵神経内分泌腫瘍における多層オミックス解析 胆と膵. 2022.02; 43 (2): 95-98. ( 医中誌 )

254. 安川紘矢、秋山好光、島田周、田中真二. 胆管癌の分子生物学的サブタイプと治療戦略 消化器・肝臓内科. 2022.01; 11 (1): 33-42.

255. 田中 真二. 【Modern Surgeon-Scientistによる恒常性維持器官の外科研究】癌幹細胞の解析と新規治療の開発 日本外科学会雑誌. 2022.01; 123 (1): 32-38. ( 医中誌 )

256. 安川 紘矢, 秋山 好光, 島田 周, 田中 真二. 【胆道疾患研究最前線】胆道癌の分子生物学的サブタイプと治療戦略 消化器・肝臓内科. 2022.01; 11 (1): 33-42. ( 医中誌 )

257. Taniai Tomohiko, Shirai Yoshihiro, Shimada Yohta, Hamura Ryoga, Yanagaki Mitsuru, Takada Naoki, Horiuchi Takashi, Haruki Koichiro, Furukawa Kenei, Uwagawa Tadashi, Tsuboi Kazuhito, Okamoto Yasuo, Shimada Shu, Tanaka Shinji, Ohashi Toya, Ikegami Toru. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells CANCER SCIENCE. 2021.11; 112 (11): 4570-4579. ( PubMed, DOI )

258. 八木　宏平, 島田　周, 下川　雅弘, 谷合　智彦, 赤星　径一, 田邉　稔, 田中　真二. 肝細胞癌治療の新展開 臨床外科. 2021.10; 76 (10): 1292-1300.

259. 石川喜也、赤星径一、浅野大輔、上田浩樹、小川康介、小野宏晃、工藤篤、田中真二、田邉稔. 肝左葉および外側区域の腹腔鏡下切除術 臨床外科増刊号　Stepごとに要点解説　標準術式アトラス最新版. 2021.10; 76 (11　増刊): 180-185.

260. 八木 宏平, 島田 周, 下川 雅弘, 谷合 智彦, 赤星 径一, 田邉 稔, 田中 真二. FOCUS　肝細胞癌治療の新展開 臨床外科. 2021.10; 76 (10): 1292-1300. ( 医中誌 )

261. 石川 喜也, 赤星 径一, 浅野 大輔, 上田 浩樹, 小川 康介, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【Stepごとに要点解説 標準術式アトラス最新版】肝臓　肝左葉および外側区域の腹腔鏡下切除術 臨床外科. 2021.10; 76 (11): 180-185. ( 医中誌 )

262. 田中 真二, 溝上 雅史, 落谷 孝広. 【肝胆膵疾患におけるバイオマーカーの意義を探る】バイオマーカー研究の最前線と臨床への導出 肝胆膵. 2021.10; 83 (4): 675-685. ( 医中誌 )

263. 赤星径一、石川喜也、浅野大輔、上田浩紀、小川康介、小野宏晃、工藤篤、田中真二、田邉稔. 右房内腫瘍栓を有する肝細胞癌手術 臨床外科. 2021.09; 76 (9): 1084-1090.

264. 赤星 径一, 石川 喜也, 浅野 大輔, 上田 浩樹, 小川 康介, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【血管外科的手技を要する肝胆膵・移植手術】肝胆膵悪性腫瘍手術　右房内腫瘍栓を有する肝細胞癌手術 臨床外科. 2021.09; 76 (9): 1084-1090. ( 医中誌 )

265. Murase Yoshiki, Kudo Atsushi, Akahoshi Keiichi, Maekawa Aya, Ishikawa Yoshiya, Ueda Hiroki, Ogawa Kosuke, Ono Hiroaki, Tanaka Shinji, Tanabe Minoru. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms ANNALS OF GASTROENTEROLOGICAL SURGERY. 2021.09; 5 (5): 692-700. ( PubMed, DOI )

266. 田中 真二. 【ここまできた肝細胞癌の薬物療法:2021 update】肝癌分子標的治療のパラドックス 肝胆膵. 2021.08; 83 (2): 159-162. ( 医中誌 )

267. Akasu Masafumi, Shimada Shu, Kabashima Ayano, Akiyama Yoshimitsu, Shimokawa Masahiro, Akahoshi Keiichi, Kudo Atsushi, Yamaoka Shoji, Tanabe Minoru, Tanaka Shinji. Intrinsic activation of beta-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma SCIENTIFIC REPORTS. 2021.08; 11 (1): 16732. ( PubMed, DOI )

268. 上田 浩樹, 森本 紘一朗, 山下 宏成, 石田 啓之, 八木 宏平, 前川 彩, 村瀬 芳樹, 石井 武, 菅原 俊喬, 石川 喜也, 赤星 径一, 小川 康介, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 70歳以上の高齢者に対する腹腔鏡下膵体尾部切除術の短期成績 日本外科学会定期学術集会抄録集. 2021.04; 121回 PS-087. ( 医中誌 )

269. 山下 宏成, 小野 宏晃, 村瀬 芳樹, 石田 啓之, 森本 紘一朗, 八木 宏平, 前川 彩, 石井 武, 菅原 俊喬, 石川 喜也, 上田 浩樹, 小川 康介, 赤星 径一, 工藤 篤, 田中 真二, 田邉 稔. 80歳以上の高齢者に対する腹腔鏡下肝切除術の治療成績 日本外科学会定期学術集会抄録集. 2021.04; 121回 PS-029. ( 医中誌 )

270. Sugawara Toshitaka, Ban Daisuke, Nishino Jo, Watanabe Shuichi, Maekawa Aya, Ishikawa Yoshiya, Akahoshi Keiichi, Ogawa Kosuke, Ono Hiroaki, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection PLOS ONE. 2021.04; 16 (4): e0249885. ( PubMed, DOI )

271. 赤星　径一, 石田　啓之, 石川　喜也, 上田　浩樹, 小川　康介, 小野　宏晃, 工藤　篤, 田中　真二, 田邉　稔. 保険診療上のルールと学会指針　院内手続きを含めて 臨床外科. 2021.03; 76 (3): 278-281.

272. 赤星 径一, 石田 啓之, 石川 喜也, 上田 浩樹, 小川 康介, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【ロボット膵切除の導入ガイド-先行施設にノウハウを学ぶ】保険診療上のルールと学会指針　院内手続きを含めて 臨床外科. 2021.03; 76 (3): 278-281. ( 医中誌 )

273. 谷合 智彦, 秋山 好光, 島田 周, 田中 真二. 【肝内胆管癌を極める】肝内胆管癌の病理　肝内胆管癌の分子生物学的特徴 肝胆膵. 2021.02; 82 (2): 261-268. ( 医中誌 )

274. 下川 雅弘, 田中 真二. 【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍　肝間葉性過誤腫 日本臨床. 2021.02; 別冊 (肝・胆道系症候群II): 241-245. ( 医中誌 )

275. 前川 彩, 渡辺 秀一, 木脇 祐子, 赤星 径一, 小川 康介, 小野 宏晃, 工藤 篤, 明石 巧, 田中 真二, 田邉 稔. brivanibの術前治療後に切除した肝細胞癌の1症例 Liver Cancer. 2021.01; 26 21-26. ( 医中誌 )

276. Amo-Shiinoki Kikuko, Tanabe Katsuya, Hoshii Yoshinobu, Matsui Hiroto, Harano Risa, Fukuda Tatsuya, Takeuchi Takato, Bouchi Ryotaro, Takagi Tokiyo, Hatanaka Masayuki, Takeda Komei, Okuya Shigeru, Nishimura Wataru, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru, Akashi Takumi, Yamada Tetsuya, Ogawa Yoshihiro, Ikeda Eiji, Nagano Hiroaki, Tanizawa Yukio. Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes JCI INSIGHT. 2021.01; 6 (1): ( PubMed, DOI )

277. 田中 真二, 山本 卓, 相田 知海, 大森 司, 福原 崇介. ゲノム編集の潮流と課題　2020年ノーベル化学賞を記念して 肝胆膵. 2021.01; 82 (1): 135-147. ( 医中誌 )

278. 田中 真二, 吉野 潤, 奥野 圭祐, 赤須 雅文, 金本 栄美, 渡辺 秀一, 伴 大輔, 工藤 篤, 絹笠 祐介, 田邉 稔. [総論]免疫チェックポイントと消化器外科　ゲノム医療・ゲノム編集時代における複合免疫治療の開発と外科臨床研究の重要性 日本消化器外科学会総会. 2020.12; 75回 WS12-9. ( 医中誌 )

279. 田中 真二, 吉野 潤, 奥野 圭祐, 赤須 雅文, 金本 栄美, 渡辺 秀一, 伴 大輔, 工藤 篤, 絹笠 祐介, 田邉 稔. [総論]免疫チェックポイントと消化器外科　ゲノム医療・ゲノム編集時代における複合免疫治療の開発と外科臨床研究の重要性 日本消化器外科学会総会. 2020.12; 75回 WS12-9. ( 医中誌 )

280. 田中 真二, 吉野 潤, 奥野 圭祐, 赤須 雅文, 金本 栄美, 渡辺 秀一, 伴 大輔, 工藤 篤, 絹笠 祐介, 田邉 稔. [総論]免疫チェックポイントと消化器外科　ゲノム医療・ゲノム編集時代における複合免疫治療の開発と外科臨床研究の重要性 日本消化器外科学会総会. 2020.12; 75回 WS12-9. ( 医中誌 )

281. 多田 稔, 中井 陽介, 中村 造, 田中 真二. 【新型コロナウイルス感染症と肝胆膵】新型コロナウイルス時代の肝胆膵診療 肝胆膵. 2020.12; 81 (6): 1041-1053. ( 医中誌 )

282. 石川 喜也, 伴 大輔, 工藤 篤, 渡辺 秀一, 上田 浩樹, 赤星 径一, 小川 康介, 小野 宏晃, 田中 真二, 田邉 稔. 【早わかり縫合・吻合のすべて】(4章)術式別の縫合・吻合法　肝臓　肝切除での大血管の吻合・縫合 臨床外科. 2020.10; 75 (11): 242-246. ( 医中誌 )

283. Kawai-Kitahata Fukiko, Asahina Yasuhiro, Kakinuma Sei, Murakawa Miyako, Nitta Sayuri, Miyoshi Masato, Sato Ayako, Tsuchiya Jun, Shimizu Taro, Takeichi Eiko, Nakagawa Mina, Itsui Yasuhiro, Azuma Seishin, Tanaka Shinji, Tanabe Minoru, Maekawa Shinya, Enomoto Nobuyuki, Watanabe Mamoru. Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection JOURNAL OF HEPATOLOGY. 2020.08; 73 S636-S637.

284. Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma Carcinogenesis. 2020.07; 41 (6): 734-742. ( DOI )

285. 工藤　篤、赤星径一、八木宏平、石井　武、前川　彩、村瀬芳樹、赤須雅文、加藤智敬、菅原俊喬、渡辺秀一、小川康介、小野宏晃、田中真二、田邉　稔. 膵神経内分泌腫瘍の長期予後と経過観察の是非 消化器・肝臓内科. 2020.06; 7 (6): 499-505.

286. Morise Z., Aldrighetti L., Belli G., Ratti F., Belli A., Cherqui D., Tanabe M., Wakabayashi G., Cheung T. T., Lo C. M., Tanaka S., Kubo S., Okamura Y., Uesaka K., Monden K., Sadamori H., Hashida K., Kawamoto K., Gotohda N., Chen K. H., Kanazawa A., Takeda Y., Ohmura Y., Ueno M., Ogura T., Suh K. S., Kato Y., Sugioka A., Nitta H., Yasunaga M., Halium N. A., Laurent A., Kaneko H., Otsuka Y., Kim K. H., Cho H. -D., Lin C. C. -W., Ome Y., Seyama Y., Troisi R. I., Berardi G., Roteller F., Wilson G. C., Geller D. A., Soubrane O., Yoh T., Kaizu T., Kumamoto Y., Han H. -S., Ekmekcigil E., Dagher I., Fuks D., Gayet B., Buell J. F., Ciria R., Briceno J., O'Rourke N., Lewin J., Edwin B., Shinoda M., Abe Y., Abu Hilal M., Alzoubi M.. Laparoscopic repeat liver resection for hepatocellular carcinoma: a multicentre propensity score-based study BRITISH JOURNAL OF SURGERY. 2020.06; 107 (7): 889-895. ( DOI )

287. 工藤 篤, 赤星 径一, 八木 宏平, 石井 武, 前川 彩, 村瀬 芳樹, 赤須 雅文, 加藤 智隆, 菅原 俊喬, 渡辺 秀一, 小川 康介, 小野 宏晃, 田中 真二, 田邉 稔. 【P-NENの新展開】膵神経内分泌腫瘍の長期予後と経過観察の是非 消化器・肝臓内科. 2020.06; 7 (6): 499-505. ( 医中誌 )

288. Matsui Satoshi, Ogura Toshiro, Ban Daisuke, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Position of the Pancreas Division Line and Postoperative Outcomes After Distal Pancreatectomy WORLD JOURNAL OF SURGERY. 2020.04; 44 (4): 1244-1251. ( PubMed, DOI )

289. 坂元 亨宇, 田中 真二, 松井 修, 千葉 哲博. 【肝細胞性腫瘍の分類・亜分類の最前線】肝細胞性腫瘍の分類・亜分類と治療選択 肝胆膵. 2020.04; 80 (4): 719-733. ( 医中誌 )

290. 田中 真二, 河野 隆志, 小俣 政男, 坂元 亨宇. 【肝胆膵領域のゲノム医療新時代-遺伝子パネルがやってきた!-】ゲノム医療によって変貌する肝胆膵の癌治療 肝胆膵. 2019.12; 79 (6): 1157-1173. ( 医中誌 )

291. 村瀬芳樹、工藤　篤、倉田盛人、赤星径一、小倉俊郎、小川康介、小野宏晃、伴　大輔、田中真二、田邉　稔. 肝転移のみを呈し5年以上生存した原発不明神経内分泌腫瘍の1症例 Liver Cancer. 2019.11; 25 53-57.

292. 石井　武、小川康介、富井翔平、今田安津子、赤須雅文、加藤智敬、浅野大輔、吉野潤、渡辺秀一、小倉俊郎、小野宏晃、光法雄介、伴　大輔、工藤　篤、田中真二、田邉　稔. 左肝管内の胆管内腫瘍栓として再発した大腸癌肝転移の1切除例 Liver Cancer. 2019.11; 25 11-15.

293. 田中 真二. 外科臨床に基づいた癌多様性の解明と治療開発 日本外科学会雑誌. 2019.11; 120 (6): 725-727. ( 医中誌 )

294. 工藤 篤, 赤星 径一, 八木 宏平, 石井 武, 前川 彩, 村瀬 芳樹, 赤須 雅文, 加藤 智敬, 菅原 俊喬, 渡辺 秀一, 小倉 俊郎, 小川 康介, 小野 宏晃, 伴 大輔, 田中 真二, 田邉 稔. 【消化器神経内分泌腫瘍を極める】膵神経内分泌腫瘍の外科治療 消化器外科. 2019.10; 42 (11): 1573-1579. ( 医中誌 )

295. 赤星 径一, 田中 真二. 【肝星細胞活性化と肝硬変・肝がん】代謝関連肝癌の腫瘍内肝星細胞の活性化 細胞. 2019.10; 51 (11): 543-546. ( 医中誌 )

296. 工藤　篤、赤星径一、八木宏平、石井　武、前川　彩、村瀬芳樹、赤須雅文、加藤智敬、菅原俊喬、渡辺秀一、小倉俊郎、小川康介、小野宏晃、伴　大輔、田中真二、田邉　稔. 膵・消化管神経内分泌腫瘍の集学的治療 臨床外科. 2019.09; 74 1092-1096.

297. 島田 周, 田中 真二. 【がん免疫療法の個別化を支える　新・腫瘍免疫学】第II部　がん免疫療法の臨床開発における課題と対応　(第3章)免疫療法のリバーストランスレーショナル研究　消化器がん(肝・胆・膵がん) 実験医学. 2019.09; 37 (15): 2596-2603. ( 医中誌 )

298. 工藤 篤, 赤星 径一, 八木 宏平, 石井 武, 前川 彩, 村瀬 芳樹, 赤須 雅文, 加藤 智隆, 菅原 俊喬, 渡辺 秀一, 小倉 俊郎, 小川 康介, 小野 宏晃, 伴 大輔, 田中 真二, 田邉 稔. 【膵・消化管神経内分泌腫瘍-診断・治療の基本と最新動向】膵・消化管神経内分泌腫瘍の集学的治療 臨床外科. 2019.09; 74 (9): 1092-1096. ( 医中誌 )

299. Yoshino Jun, Ban Daisuke, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. The Clinical Implications of Peripancreatic Fluid Collection After Distal Pancreatectomy WORLD JOURNAL OF SURGERY. 2019.08; 43 (8): 2069-2076. ( PubMed, DOI )

300. 小倉俊郎、伴　大輔、赤星径一、小川康介、小野宏晃、工藤　篤、田中真二、田邉稔. 腹腔鏡下肝胆膵手術の周術期合併症と対策 肝胆膵. 2019.07; 79 (1): 35-42.

301. 小倉 俊郎, 伴 大輔, 赤星 径一, 小川 康介, 小野 宏晃, 工藤 篤, 田中 真二, 田邉 稔. 【腹腔鏡下肝胆膵手術の新時代-ラパロからロボティクスへ-】腹腔鏡下肝胆膵手術の周術期合併症と対策 肝胆膵. 2019.07; 79 (1): 35-42. ( 医中誌 )

302. 田中 真二, 若林 剛, 中村 雅史, 永川 裕一. 【腹腔鏡下肝胆膵手術の新時代-ラパロからロボティクスへ-】新しい時代を迎えた腹腔鏡下肝胆膵手術を語る 肝胆膵. 2019.07; 79 (1): 135-147. ( 医中誌 )

303. Akahoshi Keiichi, Ban Daisuke, Kuboki Ryo, Oba Atsushi, Ono Hiroaki, Mitsunori Yusuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2019.06; 34 (6): 1108-1115. ( PubMed, DOI )

304. 赤須 雅文, 島田 周, 田中 真二. 【非ウイルス性肝細胞癌の臨床的特徴・予後】非ウイルス性肝細胞癌の発癌機構 消化器・肝臓内科. 2019.05; 5 (5): 521-526. ( 医中誌 )

305. 上田 浩樹, 秋山 好光, 田中 真二. 【膵神経内分泌腫瘍-診断と治療のパラダイムシフト-】病理と基礎　膵神経内分泌腫瘍におけるDAXX/ATRX異常とクロマチン修飾変化 肝胆膵. 2019.01; 78 (1): 39-46. ( 医中誌 )

306. 赤星 径一, 田中 真二. 【糖尿病と消化器疾患】糖尿病と肝細胞癌 消化器・肝臓内科. 2018.11; 4 (5): 417-423. ( 医中誌 )

307. Akahoshi Keiichi, Ono Hiroaki, Akasu Masafumi, Ban Daisuke, Kudo Atsushi, Konta Atsuko, Tanaka Shinji, Tanabe Minoru. Rapid growth speed of cysts can predict malignant intraductal mucinous papillary neoplasms JOURNAL OF SURGICAL RESEARCH. 2018.11; 231 195-200. ( PubMed, DOI )

308. Tamari Keisuke, Konno Masamitsu, Asai Ayumu, Koseki Jun, Hayashi Kazuhiko, Kawamoto Koichi, Murai Noriyuki, Matsufuji Senya, Isohashi Fumiaki, Satoh Taroh, Goto Noriko, Tanaka Shinji, Doki Yuichiro, Mori Masaki, Ogawa Kazuhiko, Ishii Hideshi. Polyamine flux suppresses histone lysine demethylases and enhances ID1 expression in cancer stem cells CELL DEATH DISCOVERY. 2018.11; 4 104. ( PubMed, DOI )

309. 島田 周, 芹沢 海咲, 田中 真二. 【慢性炎症から肝胆膵癌にいたるランドスケープ】癌幹細胞と免疫細胞の腫瘍宿主相関　癌幹細胞の視点から 肝胆膵. 2018.09; 77 (3): 601-609. ( 医中誌 )

310. 小倉 俊郎, 伴 大輔, 小川 康介, 小野 宏晃, 光法 雄介, 工藤 篤, 田中 真二, 田邉 稔. 【癌手術エキスパートになるための道】領域別　肝癌手術エキスパートへの道　内視鏡外科編 臨床外科. 2018.09; 73 (9): 1116-1121. ( 医中誌 )

311. 千代延 記道, 伴 大輔, 小倉 俊郎, 小川 康介, 小野 宏晃, 光法 雄介, 工藤 篤, 田中 真二, 田邉 稔. 【徹底解説! 膵尾側切除を極める】膵断端処理法　膵尾側断端被覆法 臨床外科. 2018.08; 73 (8): 958-962. ( 医中誌 )

312. 小池 和彦, 川口 巧, 建石 良介, 田中 真二. 代謝関連肝癌の実態と病態 The Liver Cancer Journal. 2018.07; 10 (1): 13-21. ( 医中誌 )

313. Mizuno Yuki, Kudo Atsushi, Akashi Takumi, Akahoshi Keiichi, Ogura Toshiro, Ogawa Kosuke, Ono Hiroaki, Mitsunori Yusuke, Ban Daisuke, Tanaka Shinji, Tateishi Ukihide, Tanabe Minoru. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2018.06; 144 (6): 1155-1163. ( PubMed, DOI )

314. Ueda Hiroki, Akiyama Yoshimitsu, Shimada Shu, Mogushi Kaoru, Serizawa Misaki, Matsumura Satoshi, Mitsunori Yusuke, Aihara Arihiro, Ban Daisuke, Ochiai Takanori, Kudo Atsushi, Tanabe Minoru, Tanaka Shinji. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs ENDOCRINE-RELATED CANCER. 2018.06; 25 (6): 619-631. ( PubMed, DOI )

315. 工藤　篤、伴　大輔、田中真二、田邉　稔. 肝胆膵の神経内分泌腫瘍の治療 病理と臨床・別刷. 2018.05; 36 (5): 437-443.

316. 工藤 篤, 伴 大輔, 田中 真二, 田邉 稔. 【神経内分泌腫瘍(NET)の病理学-治療と診断の新局面-】肝胆膵の神経内分泌腫瘍の治療 病理と臨床. 2018.05; 36 (5): 437-443. ( 医中誌 )

317. 島田 周, 田中 真二. 【肝胆膵疾患のエピジェネティクスを学ぶ】肝疾患のエピジェネティクス　癌幹細胞におけるエピゲノム異常 肝胆膵. 2018.05; 76 (5): 905-913. ( 医中誌 )

318. 全 陽, 西田 直生志, 千葉 哲博, 田中 真二. 【肝胆膵疾患のエピジェネティクスを学ぶ】肝細胞癌　Beyond the genome 肝胆膵. 2018.05; 76 (5): 953-964. ( 医中誌 )

319. 小川康介、赤星径一、小倉俊郎、光法雄介、小野宏晃、伴　大輔、工藤　篤、田中真二、田邉　稔. 肝切除における胆嚢温存 臨床外科. 2018.04; 73 (4): 482-487.

320. 赤須 雅文, 工藤 篤, 加藤 智敬, 吉野 潤, 渡邊 秀一, 水野 裕貴, 千代延 記道, 赤星 径一, 小倉 俊郎, 小川 康介, 小野 宏晃, 光法 雄介, 伴 大輔, 田中 真二, 田邉 稔. GEP-NETに対する分子標的治療薬の治療成績 日本外科学会定期学術集会抄録集. 2018.04; 118回 2392. ( 医中誌 )

321. 小川 康介, 赤星 径一, 小倉 俊郎, 光法 雄介, 小野 宏晃, 伴 大輔, 工藤 篤, 田中 真二, 田邉 稔. 【機能温存と機能再建をめざした消化器外科手術-術後QOL向上のために】肝切除における胆嚢温存 臨床外科. 2018.04; 73 (4): 482-487. ( 医中誌 )

322. 上野 絢子, 松村 聡, 渡辺 秀一, 伊藤 浩光, 光法 雄介, 藍原 有弘, 伴 大輔, 落合 高徳, 工藤 篤, 田中 真二, 田邉 稔. Duodenum inversumを合併し膵腫瘍との判別が困難であった十二指腸GISTの1例 日本臨床外科学会雑誌. 2018.03; 79 (3): 650-651. ( 医中誌 )

323. Tanaka Shinji. Precision medicine based on surgical oncology in the era o genome-scale analysis and genome editing technology ANNALS OF GASTROENTEROLOGICAL SURGERY. 2018.03; 2 (2): 106-115. ( PubMed, DOI )

324. 吉野 潤, 伴 大輔, 赤星 径一, 小倉 俊郎, 小川 康介, 小野 宏晃, 光法 雄介, 工藤 篤, 田中 真二, 田邉 稔. 【外科手術器具の理論と使用法】V.トロカール・開創器　腹部内視鏡外科手術(単孔式)に用いるアクセスポートとトロカール 外科. 2017.11; 79 (12): 1229-1232. ( 医中誌 )

325. 伊藤浩光、田中真二. 膵癌進展におけるcancer stem cellの役割 肝胆膵. 2017.10; 75 (4): 79-86.

326. 小野 宏晃, 赤須 雅文, 加藤 智敬, 水野 裕貴, 千代延 記道, 赤星 径一, 小倉 俊郎, 小川 康介, 光法 雄介, 伴 大輔, 工藤 篤, 田中 真二, 田邉 稔. 【Conversion Surgery-進行消化器がんのトータル治療戦略】がん種別Conversion Surgeryの戦略　肝細胞癌 臨床外科. 2017.10; 72 (10): 1204-1210. ( 医中誌 )

327. 伊藤 浩光, 田中 真二. 【膵癌研究Cutting Edge-from Carcinogenesis to Metastatic Colonization-】Cancer Stem Cells　膵癌進展におけるCancer Stem Cellの役割 肝胆膵. 2017.10; 75 (4): 811-819. ( 医中誌 )

328. 田中真二. ゲノム解析に基づく個別化医療の可能性　―ゲノム編集とプレシジョン・メディシン クリニシアン. 2017.09; 659 (64): 853-859.

329. 田中 真二. 【ターニングポイントを迎えた肝癌診療】ゲノム解析に基づく個別化医療の可能性　ゲノム編集とプレシジョン・メディシン クリニシアン. 2017.09; 64 (8-9): 853-859. ( 医中誌 )

330. 田邉 稔, 工藤 篤, 伴 大輔, 光法 雄介, 小野 宏晃, 小川 康介, 小倉 俊郎, 赤星 径一, 田中 真二. 「医療安全ガバナンスの確立を目指した外科組織のあり方」　医療安全ガバナンスの確立を目指した外科組織のあり方　肝胆膵外科領域の取り組み 日本外科学会雑誌. 2017.09; 118 (5): 579-581. ( 医中誌 )

331. 大畠慶映、田中真二. ソラフェニブ不応性獲得の分子メカニズム 肝胆膵. 2017.08; 75 (2): 271-280.

332. 大畠 慶映, 田中 真二. 【肝細胞癌の化学療法が変わる】ソラフェニブ治療の有効性　ソラフェニブ不応性獲得の分子メカニズム 肝胆膵. 2017.08; 75 (2): 271-280. ( 医中誌 )

333. 古山貴基、田中真二. 膵癌発生における蛋白分解メカニズムの意義 肝胆膵. 2017.07; 75 (1): 79-86.

334. Ueda Hiroki, Ban Daisuke, Kudo Atsushi, Ochiai Takanori, Tanaka Shinji, Tanabe Minoru. Refractory Long-Term Cholangitis After Pancreaticoduodenectomy: A Retrospective Study WORLD JOURNAL OF SURGERY. 2017.07; 41 (7): 1882-1889. ( PubMed, DOI )

335. 古山 貴基, 田中 真二. 【ニュートリゲノミクスから斬る肝胆膵疾患】アミノ酸代謝　膵癌発生における蛋白分解メカニズムの意義 肝胆膵. 2017.07; 75 (1): 79-86. ( 医中誌 )

336. Ishikawa Yoshiya, Ban Daisuke, Matsumura Satoshi, Mitsunori Yusuke, Ochiai Takanori, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. Surgical pitfalls of jejunal vein anatomy in pancreaticoduodenectomy JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES. 2017.07; 24 (7): 394-400. ( PubMed, DOI )

337. 田中 真二, 中尾 光善, 菅波 孝祥, 嘉数 英二. 【ニュートリゲノミクスから斬る肝胆膵疾患】ニュートリゲノミクスの研究と臨床への展望 肝胆膵. 2017.07; 75 (1): 147-160. ( 医中誌 )

338. 渡邊 秀一, 赤星 径一, 小倉 俊郎, 小川 康介, 小野 宏晃, 光法 雄介, 伴 大輔, 工藤 篤, 田中 真二, 田邉 稔. 【術後重大合併症-これだけは知っておきたい緊急処置法】肝不全 臨床外科. 2017.06; 72 (6): 725-729. ( 医中誌 )

339. 工藤　篤、伴　大輔、光法　雄介、赤星　径一、巌　康仁、小野　宏晃、佐藤　拓、水野　裕貴、千代延　記道、石川　喜也、渡辺　秀一、浅野　大輔、吉野　潤、田中　真二、田邉　稔. 膵神経内分泌腫瘍に対する術前治療と効果判定法 胆と膵. 2017.05; 38 (5): 519-525.

340. 工藤　篤、伴　大輔、光法　雄介、赤星　径一、巌　康仁、小野　宏晃、佐藤　拓、石川　喜也、渡邊　秀一、浅野　大輔、吉野　潤、田中　真二、田邉　稔. 膵神経内分泌腫瘍(P-NET)の診断、内科的治療、外科的治療最前線 消化器外科. 2017.05; 40 (6): 941-950.

341. 田邉稔、工藤篤、伴大輔、光法雄介、小野宏晃、小川康介、小倉俊郎、赤星径一、田中真二. 医療安全ガバナンスの確立を目指した外科組織のあり方 日本外科学会雑誌. 2017.05; 118 (5): 579-581.

342. 全 陽, 相島 慎一, 阪本 良弘, 田中 真二. 【混合型肝癌をめぐる混乱の終焉を目指して】混合型肝癌はどこへいくのか 肝胆膵. 2017.05; 74 (5): 669-681. ( 医中誌 )

343. 工藤 篤, 伴 大輔, 光法 雄介, 赤星 径一, 巌 康仁, 小野 宏晃, 佐藤 拓, 水野 裕貴, 千代延 記道, 石川 喜也, 渡邊 秀一, 浅野 大輔, 吉野 潤, 田中 真二, 田邉 稔. 【胆膵腫瘍に対する術前治療と切除前後の効果判定法】膵神経内分泌腫瘍に対する術前治療と効果判定法 胆と膵. 2017.05; 38 (5): 519-525. ( 医中誌 )

344. 工藤 篤, 伴 大輔, 光法 雄介, 赤星 径一, 巌 康仁, 小野 宏晃, 佐藤 拓, 石川 喜也, 渡邊 秀一, 浅野 大輔, 吉野 潤, 田中 真二, 田邉 稔. 【肝胆膵外科診療の最前線】膵神経内分泌腫瘍(P-NET)の診断、内科的治療、外科的治療最前線 消化器外科. 2017.05; 40 (6): 941-950. ( 医中誌 )

345. 伴　大輔、石川　喜也、赤星　径一、巌　康仁、小野　宏晃、光法　雄介、松村　聡、落合　高徳、工藤　篤、田中　真二、田邉　稔. 安全な腹腔鏡下肝切除導入のためのDifficulty Scoring System 臨床外科. 2017.03; 72 (3): 270-275.

346. 工藤 篤, 伴 大輔, 巌 康仁, 松村 聡, 落合 高徳, 赤星 径一, 小野 宏晃, 田中 真二, 田邉 稔. IPMNの手術適応をどう考えるべきか　国際診療ガイドラインの妥当性 日本消化器病学会雑誌. 2017.03; 114 (臨増総会): A348. ( 医中誌 )

347. 伴 大輔, 石川 喜也, 赤星 径一, 巌 康仁, 小野 宏晃, 光法 雄介, 松村 聡, 落合 高徳, 工藤 篤, 田中 真二, 田邉 稔. 【目で見る腹腔鏡下肝切除-エキスパートに学ぶ!】安全な腹腔鏡下肝切除導入のためのdifficulty scoring system 臨床外科. 2017.03; 72 (3): 270-275. ( 医中誌 )

348. 巌 康仁、赤星 径一、小野 宏晃、松村 聡、光法 雄介、伴 大輔、落合 高徳、工藤 篤、田中 真二、田邉 稔 . 特集 ビッグデータにもとづいた—術前リスクの評価と対処法 「肝機能障害」 2017.02; 72 (2): 150-156.

349. 巌 康仁, 赤星 径一, 小野 宏晃, 松村 聡, 光法 雄介, 伴 大輔, 落合 高徳, 工藤 篤, 田中 真二, 田邉 稔. 【ビッグデータにもとづいた術前リスクの評価と対処法】機能障害別　評価と対処法　肝機能障害 臨床外科. 2017.02; 72 (2): 150-156. ( 医中誌 )

350. 工藤　篤、巌　康仁、松村　聡、光法　雄介、伴　大輔、落合　高徳、田中　真二、田邉　稔. 転移性肝腫瘍の治療　NET肝転移 臨床外科. 2016.12; 71 (12): 1372-1377.

351. 田中真二. 癌幹細胞の本質とは何か？ ─ 基礎研究から臨床応用へ─ 細胞. 2016.09; 48 (9): 406-409.

352. 大庭　篤志、光法　雄介、松村　聡、藍原　有弘、伴　大輔、落合　高徳、工藤　篤、安野　正道、石川　敏昭、植竹　宏之、田中　真二、田邉　稔. 外科医が攻める高度進行大腸癌　両葉多発転移 臨床外科. 2016.08; 71 (8): 922-930.

353. 光法　雄介、巌　康仁、松村　聡、藍原　有弘、伴　大輔、落合　高徳、工藤　篤、田中　真二、田邉　稔. 腹腔鏡下胆嚢摘出後の術後胆汁漏の治療 臨床外科. 2016.07; 71 (7): 806-812.

354. 水野裕貴、田中真二. 肝発癌ポテンシャル 肝胆膵. 2016.06; 73 (6): 769-778.

355. 島田周、田中真二. ゲノム編集法を用いた肝癌治療 肝胆膵. 2016.05; 73 (5): 769-778.

356. 工藤　篤、　伴　大輔、　田中　真二、田邉　稔. 膵神経内分泌腫瘍の切除手術と薬物治療 Mebio. 2016.05; 33 (5): 86-94.

357. 島田周、田中真二. 幹細胞に注目した新薬の可能性 大腸がんperspective. 2016.04; 2 (4): 262-269.

358. 伊藤　浩光、工藤　篤、落合　高徳、伴　大輔、藍原　有弘、松村　聡、光法　雄介、田中　真二、田邉　稔. 肝胆膵悪性腫瘍に対する各種局所療法 最新医学. 2016.03; 71 (3): 392-399.

359. 工藤　篤、　伴　大輔、　田中　真二、田邉　稔. 膵神経内分泌腫瘍の肝転移の治療～適切な治療選択 内分泌・甲状腺外科. 2016.02; 33 (2): 105-109.

360. 伴　大輔、工藤　篤、巌　康仁、　田中　真二、田邉　稔. 膵頭十二指腸切除;Treitz靭帯とSMAアプローチ 消化器外科. 2016.02; 39 (2): 125-137.

361. 田邉　稔、伴　大輔、大庭　篤志、巌　康仁、小野　宏晃、光法　雄介、松村　聡、藍原　有弘、落合　高徳、工藤　篤、田中　真二. 肝胆膵領域から　完全腹腔鏡下肝左葉切除 臨床外科. 2016.01; 71 (13): 1506-1512.

362. 田中真二. 最新肝癌学-基礎と臨床の最新研究動向- Ⅳ肝癌の分子生物学 肝癌の分子生物学：概論 日本臨牀　. 2015; 73 (増刊号1): 155-163.

363. 松村聡，田中真二，田邉稔. 最新肝癌学-基礎と臨床の最新研究動向- Ⅳ肝癌の分子生物学 発癌機序 非ウイルス性肝癌発生の分子生物学的メカニズム 日本臨牀. 2015; 73 (増刊号１): 203-207.

364. 田中真二. 【特集／肝がん：診断と治療の進歩】病因と病態－最近の遺伝子解析を中心に． 日本内科学会雑誌. 2014; 66 (6): 917-925.

365. 田中真二, 勝田絵里子, 工藤篤, 田邉稔, 有井滋樹. 【特集／肝胆膵診療のNew Horizon】膵神経内分泌腫瘍．保険収載されたエベロリムス、スニチニブ、オクトレオチドLARを如何に使うか？ 肝胆膵. 2014; 69 (6): 1220-1227.

366. 田中真二, 有井滋樹. 【特集／膵癌退治のはじまり】分子標的治療の現状． 肝胆膵. 2014; 68 (6): 949-958.

367. 田中真二, 有井滋樹. 【特集／肝胆膵領域におけるNF-κB研究の最前線】肝細胞癌におけるNF-κB活性亢進と癌幹細胞性への関与． 肝胆膵. 2014; 68 (4): 599-607.

368. 田中真二，有井滋樹. 【特集／肝胆膵腫瘍のバイオインフォマティクス】早期膵癌の分子マーカー． 肝胆膵. 2014; 68 (3): 401-408.